UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 10-Q

  

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 20172019

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________ to _________

 

Commission File Number: 001-37941

  

SENESTECH, INC. 

(Exact name of registrant as specified in its charter)

  

Delaware 20-2079805

(State or other jurisdiction of


incorporation or organization)

 

(I.R.S. Employer


Identification No.)

   

3140 N. Caden Court, Suite 1
Flagstaff, AZ
 86004
(Address of principal executive offices) (Zip Code)

 

(928) 779-4143

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each classTrading Symbol(s)Name of each exchange on which
registered
Common Stock, $0.001 par valueSNESThe NASDAQ Stock Market LLC
(NASDAQ Capital Market)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒   No  ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes   ☒   No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  Accelerated filer
Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒    

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

  

The number of shares of common stock outstanding as of November 7, 2017: 10,389,49714, 2019: 28,288,596

  

 


 

SENESTECH, INC.

FORM 10-Q

For the Quarterly Period Ended September 30, 20172019

 

TABLE OF CONTENTS

 

  Page
 PART I. FINANCIAL INFORMATION31
Item 1Financial Statements31
Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations2819
Item 3Quantitative and Qualitative Disclosures About Market Risk3930
Item 4Controls and Procedures39
PART II. OTHER INFORMATION39
Item 1ARisk Factors39
Item 5Other Information40
Item 6Exhibits41
Index to Exhibits4130
 SignaturesPART II. OTHER INFORMATION4231
Item 1Legal Proceedings31
Item 1ARisk Factors31
Item 2Unregistered Sales of Equity Securities and Use of Proceeds31
Item 3Defaults Upon Senior Securities31
Item 4Mine Safety Disclosures31

i

 


 

PART I. FINANCIAL INFORMATION

Item 1.Financial Statements

 

Item 1.       Financial Statements

SENESTECH, INC.

CONDENSED BALANCE SHEETS

(In thousands, except shares and per share data)

 

 September 30, December 31, 
 2019  2018 
 September 30,
2017
  December 31,
2016
  (Unaudited)    
ASSETS  (Unaudited)        
             
Current assets:             
Cash $699  $11,826  $3,945  $4,920 
Investment in securities held to maturity  2,949    
Accounts receivable  7   10   155   139 
Prepaid expenses  172   337   304   342 
Inventory  394   57   1,285   1,261 
Deposits  17   9   6   9 
Total current assets  4,238   12,239   5,695   6,671 
                
Right to use asset-operating leases  29   - 
Property and equipment, net  1,559   631   830   1,083 
Total assets $5,797  $12,870  $6,554  $7,754 
                
LIABILITIES AND STOCKHOLDERS’ EQUITY                
                
Current liabilities:                
Short-term debt $174  $45  $129  $219 
Accounts payable  175   351   291   173 
Accrued contract cancellation settlement     1,000 
Accrued expenses  1,074   371   785   771 
Notes payable, related parties  18   30 
Total current liabilities  1,441   1,797   1,205   1,163 
                
Notes payable, related parties     6 
Long-term debt, net  637   138   167   261 
Operating lease liability  29   - 
Common stock warrant liability  4   69   -   - 
Deferred rent  45   33   5   16 
Total liabilities  2,127   2,043   1,406   1,440 
                
Commitments and contingencies (See note 15)      
Commitments and contingencies (See note 12)  -   - 
                
Stockholders’ equity:                
        
Common stock, $0.001 par value, 100,000,000 shares authorized, 10,363,189 and 10,157,292 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively  10   10 
Common stock, $0.001 par value, 100,000,000 shares authorized, 28,288,285 and 23,471,999 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively  28   24 
Additional paid-in capital  74,946   72,069   98,196   92,128 
Stock subscribed, but not issued, consisting of -0- and 4,750 shares at September 30, 2017 and December 31, 2016, respectively     59 
Accumulated deficit  (71,286)  (61,311)  (93,076)  (85,838)
Total stockholders’ equity  3,670   10,827   5,148   6,314 
                
Total liabilities and stockholders’ equity $5,797  $12,870  $6,554  $7,754 

 

See accompanying notes to financial statements.


SENESTECH, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except shares and per share data)

(Unaudited)

 

  For the Three Months
Ended September 30,
  For the Nine Months
Ended September 30,
 
  2017  2016  2017  2016 
Revenue:            
License revenue $  $131  $  $261 
Product Sales  17      34    
Total revenue  17   131   34   261 
Cost of goods sold  11      27    
Gross profit  6   131   7   261 
                 
Operating expenses:                
Research and development  721   829   2,517   1,964 
General and administrative  2,235   1,932   7,506   5,259 
Total operating expenses  2,956   2,761   10,023   7,223 
                 
Net operating loss  (2,950)  (2,630)  (10,016)  (6,962)
                 
Other income (expense):                
Interest income  9      20    
Interest expense  (33)  (6)  (54)  (49)
Interest expense, related parties     (9)  (1)  (43)
Loss on extinguishment of unsecured promissory note     (59)     (171)
Other income (expense)  37      76   51 
Total other income (expense)  13   (74)  41   (212)
                 
Net loss  (2,937)  (2,704)  (9,975)  (7,174)
                 
Series A convertible preferred stock dividends     (30)     (90)
                 
Net loss and comprehensive loss $(2,937) $(2,734) $(9,975) $(7,264)
                 
Weighted average common shares outstanding - basic and fully diluted  10,334,211   7,306,234   10,234,211   5,774,738 
                 
Net loss per common share - basic and fully diluted $(0.28) $(0.37) $(0.97) $(1.26)

  For the Three Months  For the Nine Months 
  Ended September 30,  Ended September 30, 
  2019  2018  2019  2018 
             
Revenue:            
Sales $36  $105  $79  $160 
Cost of sales  25   114   58   153 
Gross profit (loss)  11   (9)  21   7 
                 
Operating expenses:                
Research and development  432   476   1,359   1,746 
Selling, general and administrative  2,173   2,013   5,908   7,506 
Total operating expenses  2,605   2,489   7,267   9,252 
                 
Net operating loss  (2,594)  (2,498)  (7,246)  (9,245)
                 
Other income (expense):                
Interest income  19   1   45   8 
Interest expense  (10)  (16)  (34)  (60)
Other income (expense)  -   13   (3)  19 
Total other income (expense)  9   (2)  8   (33)
                 
Net loss and comprehensive loss  (2,585)  (2,500)  (7,238)  (9,278)
Deemed dividend-warrant price protection adjustment  -   333   -   333 
Net loss attributable to common shareholders $(2,585) $(2,833) $(7,238) $(9,611)
                 
                 
Weighted average common shares outstanding - basic and fully diluted  27,891,501   20,862,216   25,336,837   18,036,982 
                 
Net loss per common share - basic and fully diluted $(0.09) $(0.14) $(0.29) $(0.53)

 

See accompanying notes to financial statements.


SENESTECH, INC.

STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

(In thousands, except shares and per share data)

(Unaudited)

 

SENESTECH, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)For The Three Months Ended September 30, 2018 and 2019

 

  For the Nine Months 
  Ended September 30, 
  2017  2016 
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss $(9,975) $(7,174)
Adjustments to reconcile net loss to net cash used in operating activities:        
Gain on investments held to maturity  (20)   
Amortization of discounts on investments held to maturity  11    
Depreciation and amortization  273   143 
Stock-based compensation  2,818   2,406 
Non-cash charge for settlement of dispute     300 
Amortization of debt discount     27 
Gain on remeasurement of common stock warrant liability  (65)  (51)
Loss on extinguishment of unsecured promissory note     171 
(Increase) decrease in current assets:        
Accounts receivable  3   (4)
Prepaid expenses  165   (17)
Inventory  (337)   
Deposits  (8)   
Increase (decrease) in current liabilities:        
Accounts payable  (176)  77 
Accrued contract cancellation settlement  (1,000)   
Accrued expenses  703   61 
Deferred rent  12   (4)
Deferred revenues     (175)
Net cash used in operating activities  (7,596)  (4,240)
         
CASH FLOWS FROM INVESTING ACTIVITIES        
Purchase of securities held to maturity  (2,940)   
Purchase of property and equipment  (885)  (54)
Net cash used in investing activities  (3,825)  (54)
         
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from the issuance of series B convertible preferred stock     896 
Proceeds from the issuance of common stock     6,199 
Proceeds from the issuance of convertible notes payable     326 
Repayments of convertible notes payable     (810)
Proceeds from the issuance of notes payable  437    
Repayments of notes payable  (48)  (24)
Repayments of notes payable, related parties  (18)  (721)
Repayments of capital lease obligations  (77)  (16)
Payment of deferred offering costs     (801)
Proceeds from exercise of stock options and warrants     449 
Net cash provided by financing activities  294   5,498 
         
NET CHANGE IN CASH  (11,127)  1,204 
CASH AT BEGINNING OF PERIOD  11,826   141 
CASH AT END OF PERIOD $699  $1,345 
         
         
SUPPLEMENTAL INFORMATION:        
Interest paid $55  $23 
Income taxes paid $  $ 
         
NON-CASH INVESTING AND FINANCING ACTIVITIES:        
Purchases of equipment under capital lease obligations $316  $157 
Original issue discount $  $147 
Debt discount on convertible notes $  $9 
Related party convertible note extinguished for settlement payable $  $404 
Contributed capital, debt forgiveness by related parties $  $2,003 
Issuance of series B convertible preferred stock in connection with conversion of convertible notes and $  $16 
Issuance of shares of common stock upon conversion of Series B convertible preferred stock $  $260 
Dividends $  $90 
        Additional  Stock     Total Stockholders’ 
  Common Stock  Paid-In  Subscription  Accumulated  Equity 
  Shares  Amount  Capital  Payable  Deficit  (Deficit) 
Balance, June 30, 2018  18,040,497  $18  $86,022  $-  $(80,375) $5,665 
                         
Issuance of common stock for services  27,738   -   -   -   -   - 
Stock-based compensation  -   -   355   -   -   355 
Issuance of common stock, sold for cash, net  5,357,052   5   5,127   -   -   5,132 
Warrant antidilution price protection adjustment          333       (333)  - 
Payments for employee withholding taxes related to share-based awards.  -   -   (15)  -   -   (15)
Net loss for the three months ended September 30, 2018  -   -       -   (2,500)  (2,500)
Balance, September 30, 2018  23,425,287  $23  $91,822  $-  $(83,208) $8,637 
                         
Balance, June 30, 2019  25,227,475  $25  $94,391  $-  $(90,491) $3,925 
                         
Issuance of common stock, sold for cash, net  3,037,038  $3  $3,627  $-       3,630 
Issuance of common stock for services  19,258   -   -   -   -   - 
Stock-based compensation  -   -   204   -   -   204 
Issuance of common stock upon exercise of warrants  4,514   -   5   -   -   5 
Payments for employee withholding taxes related to share-based awards  -   -   (31)  -   -   (31)
Net loss for the three months ended September 30, 2019  -   -   -   -   (2,585)  (2,585)
Balance, September 30, 2019  28,288,285  $28  $98,196  $-  $(93,076) $5,148 
                         
For The Nine Months Ended September 30, 2018 and 2019                        
                         
Balance, December 31, 2017  16,404,195  $16  $81,103  $-  $(73,597) $7,522 
                         
Issuance of common stock, sold for cash, net  5,357,052   5   5,127           5,132 
Issuance of common stock for services  174,481   1   34   (8)  -   27 
Stock-based compensation  -   -   3,062   -   -   3,062 
Stock subscribed but not issued  -   -   (8)  8   -   - 
Issuance of common stock upon cashless exercise of stock options  13,900   -   -   -   -   - 
Issuance of common stock upon exercise of warrants  1,475,659   1   2,213   -   -   2,214 
Payments for employee withholding taxes related to share-based awards  -   -   (42)  -   -   (42)
Warrant antidilution price protection adjustment          333       (333)    
Net loss for the nine months ended September 30, 2018  -   -   -   -   (9,278)  (9,278)
Balance, September 30, 2018  23,425,287  $23  $91,822  $-  $(83,208) $8,637 
                         
Balance, December 31, 2018  23,471,999  $24  $92,128  $-  $(85,838) $6,314 
                         
Issuance of common stock, sold for cash, net  3,037,038  $3  $3,627           3,630 
Issuance of common stock for services  144,054   -   34   -   -   34 
Stock-based compensation  -   -   675   -   -   675 
Issuance of common stock upon exercise of warrants  1,610,210   1   1,787   -   -   1,788 
Issuance of common stock upon exercise of stock options  24,984   -   -   -   -   - 
Payments for employee withholding taxes related to share-based awards  -   -   (55)  -   -   (55)
Net loss for the nine months ended September 30, 2019  -   -   -   -   (7,238)  (7,238)
Balance, September 30, 2019  28,288,285  $28  $98,196  $-  $(93,076) $5,148 

The accompanying notes are an integral part of these financial statements.

 

See accompanying notes to financial statements.


SENESTECH, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

  

  For the Nine Months 
  Ended September 30, 
  2019  2018 
CASH FLOWS FROM OPERATING ACTIVITIES      
Net loss $(7,238) $(9,278)
Adjustments to reconcile net loss to net cash used in operating activities:        
Gain on investments held to maturity  -   (44)
Depreciation and amortization  314   332 
Stock-based compensation  675   3,090 
Loss on sale of equipment  3   15 
Loss on early extinguishment of debt  -   10 
Loss on remeasurement of common stock warrant liability  -   1 
(Increase) decrease in current assets:        
Accounts receivable  (16)  (36)
Prepaid expenses  38   (166)
Inventory  (24)  (578)
Deposits  3   7 
Increase (decrease) in current liabilities:        
Accounts payable  118   (185)
Accrued expenses  46   (66)
Deferred rent  (11)  (18)
Net cash used in operating activities  (6,092)  (6,916)
         
CASH FLOWS FROM INVESTING ACTIVITIES        
Proceeds received on sale of securities held to maturity  -   2,619 
Proceeds received on sale of equipment  -   185 
Purchase of property and equipment  (64)  (212)
Net cash provided by (used in) investing activities  (64)  2,592 
         
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from the issuance of common stock, net  3,631   5,132 
Proceeds from the issuance of notes payable      9 
Repayments of notes payable  (184)  (236)
Repayments of notes payable, related parties  -   (12)
Repayments of capital lease obligations  -   (50)
Proceeds from the exercise of warrants  1,789   2,213 
Payment of employee withholding taxes related to share-based awards  (55)  (42)
Net cash provided by financing activities  5,181   7,014 
         
NET CHANGE IN CASH  (975)  2,690 
CASH AT BEGINNING OF PERIOD  4,920   2,101 
CASH AT END OF PERIOD $3,945  $4,791 
         
SUPPLEMENTAL INFORMATION:        
Interest paid $34  $60 
Income taxes paid $-  $- 
         
NON-CASH INVESTING AND FINANCING ACTIVITIES:        
    Deemed dividend     $333 
Purchases of equipment under capital lease obligations $-  $37 
Common stock issued on accrued bonus $32  $- 

See accompanying notes to financial statements.


SENESTECH, INC.

 

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 1 - Organization and Description of Business

 

SenesTech, Inc. (the “Company”(referred to in this report as “SenesTech,” the “Company,” “we” or “us”) was formed in July 2004 and incorporated in the state of Nevada. The Company subsequently reincorporated in the state of Delaware in November 2015. The Company has itsOur corporate headquarters is in Flagstaff, Arizona.

The Company has We have developed and are commercializing a global, proprietary technology for managing animal pest populations, initially rat populations, through fertility control. The Company believes that its innovative non-lethal approach, targeting reproduction, is more humane, less harmful

Although myriad tools are available to fight rat infestations, communities, food producers, zoos and sanctuaries and others continue to face challenges in controlling today’s infestations. Infestations result in significant infrastructure damage, as well as pose additional risks to the environment,health and more effectivefood security of communities. In addition to these challenges, the pest management industry and pest management professionals (PMPs) are being increasingly asked for new solutions to help solve the problem. With growing concerns about rat resistance to rodenticides and a growing interest in providingnon-lethal options, it is becoming increasingly important for PMPs to have new tools at their disposal. Our goal is to provide customers with not only a sustainable solution to pestcombat their most difficult infestations, than traditional lethalbut also offer a non-lethal option to serve customers that are looking to decrease or remove the amount of poison used in their pest management methods. Itsprograms.

Our first fertility control product, candidate, ContraPest, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (VCD) and triptolide. When consumed, ContraPest targets reproduction, limiting fertility in male and female rats beginning with the first breeding cycle following consumption. ContraPest is being marketed for use in controlling rat populations, specifically Norway and roof rats. On August 23, 2015, the rat population. The innovative compound is consumed by rats and leaves them non-reproductive without other observable side effects. The U.S.United States Environmental Protection Agency (“EPA”)(EPA) granted registration approval for ContraPest as a Restricted Product Due to Professional Expertise (referred to in this report as a “Restricted Use designation”), effective August 2, 2016. The Company plansOn October 18, 2018, the EPA approved the removal of the Restricted Use designation. We believe ContraPest is the first and only non-lethal fertility control product approved by the EPA for the management of rodent populations.

In addition to the EPA registration of ContraPest in the United States, we must obtain registration from the various state regulatory agencies prior to selling in each state. As of the date of this report, we have received registration for ContraPest in all 50 states and the District of Columbia, 47 of which have approved the removal of the Restricted Use designation.

We expect to continue to commercializepursue regulatory approvals and distribute ContraPest by leveraging new andamendments to existing third-party relationships with manufacturing, marketing and distribution partnersregistration in the U.S.United States for ContraPest, and internationally.if ContraPest begins to generate sufficient revenue, regulatory approvals for any additional jurisdictions beyond the United States.

 

Potential Need for Additional Capital

 

InSince our inception, we have sustained significant operating losses in the course of itsour research and development and commercialization activities the Company has sustained operating losses since its inception and expectsexpect such losses to continue for the near future. The Company’sWe have generated limited revenue to date from product sales, research grants and licensing fees received under our former license agreement with Neogen. In 2017, we began to prepare and launch commercialization of our first product, ContraPest. We have primarily funded our operations to date through the sale of equity securities, including convertible preferred stock, common stock and warrants to purchase common stock.

We have also raised capital through debt financing, consisting primarily of convertible notes; and, to a lesser extent, payments received in connection with product sales, research grants and licensing fees.

Through September 30, 2019, we had received net proceeds of $67.2 million from sales of our common stock, preferred stock and warrant exercises and issuance of convertible and other promissory notes, an aggregate of $1.7 million from licensing fees and an aggregate of $0.5 million in net product sales. At September 30, 2019, we had an accumulated deficit of $93.1 million and cash and cash equivalents of $3.9 million.

Our ultimate success depends upon the outcome of a combination of factors, including: (i) the success of its research and development; (ii) ongoing regulatory approval andsuccessful commercialization of ContraPest and its othermaintaining and obtaining regulatory approvals of our products and product candidates; (iii)candidates, (ii) market acceptance, and commercial viability and profitability of ContraPest and other products if the Company obtains the necessary regulatory approvals; (iv)products; (iii) the ability to market itsour products and establish an effective sales force and marketing infrastructure to generate significant revenue; (iv) the success of our research and development; (v) theour ability to retain and attract key personnel to develop, operate and grow itsour business; and (vi) our ability to meet our working capital needs.

Based upon our current operating plan, we expect that cash and cash equivalents at September 30, 2019, in combination with anticipated revenue and any additional sales of our equity securities, will be sufficient to fund our current operations for at least the timelynext six months. We have taken and will continue to take actions to reduce our operating expenses and to concentrate our resources toward the successful completioncommercialization of additional financing. The Company has funded its operationsContraPest in the U. S. However, if anticipated revenue targets and margin targets are not achieved and we are unable to dateraise necessary capital through the sale of convertible preferred stockour securities, we may be required take other measures that could impair our ability to be successful and common stock, including an initial public offering of 1,875,000 shares of its common stock on December 8, 2016, debt financing, consisting primarily of convertible notes and, tooperate as a lesser extent, payments received in connection with research grants and licensing fees. As of September 30, 2017, the Company had cash and cash equivalents and highly liquid investments of $3,648. However, the Company isgoing concern. In any event, we are likely to require additional capital in order to fund itsour operating losses and research and development activities by issuing additionaluntil we become profitable. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to need to raise capital through equity or debt and equity instruments until such time as the Company is profitable.financing. If such equity or debt financing is not available at adequate levels the Company willor on acceptable terms, we may need to reevaluate its plans.delay, limit or terminate commercialization and development efforts.

 

All amounts shown in these financial statements are in5

SENESTECH, INC.

 NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except percentagesshare and per share data)

Note 1 - Organization and share amounts. Per share and share amounts reflect post-reverse split values.Description of Business – (continued)

 

Basis of Presentation

 

The accompanying unaudited condensed financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the Company’s opinion, the unaudited condensed financial statements include all material adjustments, all of which are of a normal and recurring nature, necessary to present fairly the Company’s financial position as of September 30, 2017,2019, the Company’s operating results for the three and nine months ended September 30, 20172019 and 2016,2018, and the Company’s cash flows for the nine months ended September 30, 20172019 and 2016.2018. The accompanying financial information as of December 31, 20162018 is derived from audited financial statements. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K, as amended by Form 10-K/A, for the year ended December 31, 2016.

2018, both filed with the SEC on March 29, 2019. All amounts shown in these financial statements and accompanying notes are in thousands, except percentages and per share and share amounts.

SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS 

(In thousands, except share and per share data)

 

Note 2 - Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”)GAAP requires management to make estimates and assumptions that affect the reported amounts and classification of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The significant estimates in the Company’s financial statements include the valuation of preferred stock, common stock and related warrants, and other stock-based awards. Actual results could differ from such estimates.

 

Reclassifications

 

Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no material impact on net earnings, financial position or cash flows.

Deferred Offering Costs

Deferred offering costs consisted primarily of legal, accounting and other direct and incremental fees and costs related to the Company’s initial public offering on December 8, 2016. Deferred offering costs of $2,234 were offset against the proceeds received from the initial public offering in December 2016.There were no deferred offering costs at September 30, 2017.

Cash and Cash Equivalents

The Company considers money market fund investments to be cash equivalents. The Company had cash equivalents of $70 and $-0- at September 30, 2017 and December 31, 2016, respectively, included in cash as reported.

Investments in Securities Held to Maturity

The Company uses cash holdings to purchase highly liquid, short term, investment grade securities diversified among security types, industries and issuers. All of the Company’s investment securities are measured at fair value. The Company’s investment securities primarily consist of municipal debt securities, corporate bonds, U.S. agency securities and commercial paper and highly-liquid money market funds.

 

Accounts Receivable

 

Accounts receivable consist primarily of trade receivables. The Company provides an allowance for doubtful trade receivables equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions and a review of the current status of each customer’s trade accounts receivable. The allowance for doubtful trade receivables was $3 and $-0- as ofless than $1 at September 30, 20172019 and at December 31, 2016, respectively.2018.

 

Inventories

 

Inventories are stated at the lower of cost or market value, using the first-in, first-out convention. Inventories consist of raw materials, work in progress and finished goods. As of September 30, 2017 and December 31, 2016, the Company had inventories of $394 and $57, respectively.

 

SENESTECH, INC.Components of inventory are:

 

NOTES TO CONDENSED FINANCIAL STATEMENTS 

(In thousands, except share and per share data)

Note 2 - Summary of Significant Accounting Policies – (continued)

  September 30,  December 31, 
  2019  2018 
Raw materials $1,063  $1,111 
Work in progress  3    
Finished goods  223   154 
Total inventory  1,289   1,265 
Less:        
Reserve for obsolete  (4)  (4)
Total net inventory $1,285  $1,261 

 

Prepaid Expenses

 

Prepaid expenses consist primarily of payments made for director and officer insurance, director compensation, rent, legal and inventory purchase deposits and seminar fees to be expensed in the current year.


SENESTECH, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(In thousands, except share and per share data)

Note 2 - Summary of Significant Accounting Policies – (continued)

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Equipment held under capital leases are stated at the present value of minimum lease payments less accumulated amortization.

 

Depreciation on property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. The cost of leasehold improvements is amortized over the life of the improvement or the term of the lease, whichever is shorter. Equipment held under capital leases is amortized over the shorter of the lease term or estimated useful life of the asset. The Company incurs repair and maintenance costs on its major equipment. Repair and maintenance costsequipment, which are expensed as incurred.

 

Impairment of Long-Lived Assets

 

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require long-lived assets or asset groups to be tested for possible impairment, the Company compares the undiscounted cash flows expected to be generated from the use of the asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques, such as discounted cash flow models and the use of third- partythird-party independent appraisals. The Company has not recorded an impairment of long-lived assets since its inception.

 

Revenue Recognition

 

TheEffective January 1, 2018, the Company adopted ASC 606 —Revenue from Contracts with Customers.Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 —Revenue Recognition.Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of the fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured.

SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS 

(In thousands, except share The performance obligations identified by the Company under Accounting Standards Codification (“ASC”) Topic 606, Revenue From Contracts With Customers, are straightforward and per share data)

Note 2 - Summarysimilar to the unit of Significant Accounting Policies – (continued)account and performance obligation determination under ASC Topic 605,Revenue Recognition. There was no impact on the Company’s financial statements as a result of adopting ASC 606 for the three months or nine months ended September 30, 2019 and 2018, respectively.

 

The Company has generatedrecognizes revenue fromwhen product leaves its dock at a license agreement with a strategic partner, pursuant to which the Company had granted to such partner the exclusive right to manufacture and distribute its product, ContraPest, once the required regulatory approvals were received. This licensing agreement was subsequently terminatedfixed selling price on January 23, 2017. Thepayment terms of the licensing agreement contained multiple elements or deliverables, as discussed below. Management evaluates whether the arrangement involving the multiple deliverables contains more than one unit of accounting. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances of the arrangement.

The Company determined that the license granted pursuant30 to the license agreement did not have stand-alone value and, therefore, the nonrefundable, upfront license fee payments received by the Company are recognized on a straight-line basis over the estimated related performance period (i.e.120 days from the effective date of the agreement through the estimated completion date of the Company’s substantive performance obligations).

In accordance with the terms of the license agreement, the Company was also to receive a future fixed amount of contingent milestone payments (i.e. post-regulatory approval license fees) and contingent sales-based royalties to be received upon the achievement of certain milestone events. The milestone events under the agreement include regulatory approval, patent issuance or alternative intellectual property coverage, and sales-based events. The Company did not earn or receive any of the potential contingent milestone payments, as the milestone events to receive such post-approval license fees and sales-based royalties were not achieved. The Company recognizes revenue that is contingent upon the achievement of a substantive milestone event in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to the Company for such milestone has all of the following characteristics: (i) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved; (ii) the event can only be achieved based in whole or part on either the Company’s performance or a specific outcome resulting from the Company’s performance; and (iii) if achieved, the event would result in additional payments being due to the Company. As the potential contingent consideration was to be received only upon the achievement of milestone events that are considered substantive, the Company would only recognize such revenue in the period the milestone is achieved and the milestone payments became due and collectible. In addition, the Company accounts for sales-based royalties as revenue upon achievement of certain sales milestones. 

Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the balance sheet. Amounts expected to be recognized as revenue in the next twelve months following the balance sheet date are classified as a current liability.

invoicing. The Company recognizes other revenue earned from pilot studies upon the performance of specific services under the respective service contract.

 

For the nine months ended September 30, 2017, theThe Company generated net revenuesderives revenue primarily from commercial sales of $34.products.

 

Research and Development

 

Research and development costs are expensed as incurred. Research and development expenses primarily consist of salaries and benefits for research and development employees, stock-based compensation, consulting fees, lab supplies, and costs incurred related to conducting scientific trials and field studies, and regulatory compliance costs. Also, included in research and development expenses is an allocation of facilities related costs, including depreciation of research and development equipment.

SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS 

(In thousands, except share and per share data)

Note 2 - Summary of Significant Accounting Policies – (continued)

 

Stock-based Compensation

 

Employee stock-based awards, consisting of restricted stock units and stock options expected to be settled in shares of the Company’s common stock, are recorded as equity awards. The grant date fair value of these awardsstock options is measured using the Black-Scholes option pricing model. The Company expenses the grant date fair value of its stock options on a straight-line basis over their respective vesting periods. Performance-based awards are expensed over the performance period when the related performance goals are probable of being achieved.

 

For equity instruments issued to non-employees, the stock-based consideration is measured using a fair value method. The measurement of the stock-based compensation is subject to re-measurement as the underlying equity instruments vest.

 


SENESTECH, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(In thousands, except share and per share data)

Note 2 - Summary of Significant Accounting Policies – (continued)

The stock-based compensation expense recorded for the three and nine months ended September 30, 20172019 and 2016 2018,

is as follows:

 

 Three Months Ended
September 30,
 Nine Months Ended
September 30,
  Three Months Ended
September 30,
 Nine Months Ended
September 30,
 
 2017  2016  2017  2016  2019  2018  2019  2018 
                  
Research and development $85  $135  $269  $309  $1  $29  $11  $87 
General and administrative  861   798   2,549   2,097   203   326   661   3,003 
Total stock-based compensation expense $946  $933  $2,818  $2,406  $204  $355  $675  $3,090 

See Note 11 for additional discussion on stock-based compensation.

 

Income Taxes

 

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statementsstatement and tax bases of assets and liabilities and net operating loss carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date.

 

The Company records net deferred tax assets to the extent it believes these assets will more likely than not be realized. These deferred tax assets are subject to periodic assessments as to recoverability and if it is determined that it is more likely than not that the benefits will not be realized, valuation allowances are recorded which would increase the provision for income taxes. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. The Company currently maintains a full allowance against its deferred tax assets.

 

10 

SENESTECH, INC.The Company applies a more-likely-than-not recognition threshold for all tax uncertainties. Only those benefits that have a greater than fifty percent likelihood of being sustained upon examination by the taxing authorities are recognized. Based on its evaluation, the Company has concluded there are no significant uncertain tax positions requiring recognition in its financial statements.

 

NOTES TO CONDENSED FINANCIAL STATEMENTS 

(In thousands, except shareThe Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There are no uncertain tax positions as of September 30, 2019 or December 31, 2018 and per share data)

Note 2 - Summary of Significant Accounting Policies – (continued)as such, no interest or penalties were recorded in income tax expense.

 

Comprehensive Loss

 

Net loss and comprehensive loss were the same for all periods presented; therefore, a separate statement of comprehensive loss is not included in the accompanying financial statements.

 

Loss Per Share Attributable to Common Stockholders

 

Basic loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per share attributable to common stockholders is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock and if-converted methods. For purposes of the computation of diluted loss per share attributable to common stockholders, the Series A convertible preferred stock (prior to its conversion into common stock), Series B convertible preferred stock (prior to its conversion into common stock), convertible promissory notes (prior to their conversion), common stock purchase warrants, and common stock options are considered to be potentially dilutive securities but have been excluded from the calculation of diluted loss per share attributable to common stockholders because their effect would be anti-dilutive given the net loss reported for the three and nine months ended September 30, 20172019 and 2016.2018. Therefore, basic and diluted loss per share attributable to common stockholders wasare the same for all periodseach period presented.

 

The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted loss per share attributable to common stockholders (in common stock equivalent shares):

 

 September 30,  September 30, 
 2017  2016  2019  2018 
Series A convertible preferred stock     400,000 
Series B convertible preferred stock     483,609 
Common stock purchase warrants  829,285   750,185   9,783,278   11,714,940 
Restricted stock units  344,982    
Restricted stock unit  117,465   172,912 
Common stock options  1,558,800   1,321,300   2,747,677   1,725,771 
Total  2,733,067   2,955,094   12,648,420   13,613,623 

 

11 


SENESTECH, INC.


NOTES TO CONDENSED FINANCIAL STATEMENTS


(In thousands, except share and per share data)

 

Note 2 - Summary of Significant Accounting Policies – (continued)

 

Adoption of New Accounting Standards:

In May 2017,2014, the FASB issued Accounting Standard Update (“ASU”)No.ASU 2014-09,2017-9,Revenue from Contracts with CustomersCompensation — Stock Compensation (Topic 718): Scope. Since ASU 2014-09 was issued, several additional ASUs have been issued to clarify various elements of Modification Accounting (“ASU2017-9”), which providesthe guidance. These standards provide guidance about which changeson recognizing revenue, including a five-step model to the terms or conditions of a share-based payment award requiredetermine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to apply modification accountingdepict the transfer of control of promised goods or services to customers in Topic 718.Peran amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Effective January 1, 2018, the Company adopted ASU 2017-9, an entity should account for2014-09,“Revenue from Contracts with Customers”using the effects of a modification unlessmodified retrospective method to all the following are met: (1) the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used)contracts that were not completed as of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used)date of the original award immediately before the original award is modified. If the modification does not affect anyadoption. The results of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before andoperations for reported periods after the modification, (2) the vesting conditions of the modified awardJanuary 1, 2018 are the same as the vesting conditions of the original award immediately before the original award is modified, and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The current disclosure requirementspresented under this amended guidance, while prior period amounts are reported in Topic 718 apply regardless of whether an entity is required to apply modification accounting under the amendments in ASU 2017-9.ASU 2017-9 is effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017.Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this ASU should be applied prospectively to an award modified on or after the adoption date. The adoption ofaccordance with ASC 605 —ASU 2017-9Revenue Recognition is not expected to have a. There was no material impact on the Company’sour financial statementsposition, results of operations, or related disclosures.cash flows.

 

In AugustJanuary 2016, the FASB issued ASU No. 2016-15,2016-01,StatementRecognition and Measurement of Cash Flows (Topic230): ClassificationFinancial Assets and Financial Liabilities(“ASU 2016-01”). This standard affects the accounting for equity instruments, financial liabilities under the fair value option and the presentation and disclosure requirements of Certain Cash Receipts and Cash Payments.financial instruments. ASU 2016-01 is effective the first quarter of 2018. The amendments in this ASU provide guidance onCompany has adopted the following eight specific cash flow classification issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. Current GAAP does not include specific guidance on these eight cash flow classification issues. The amendments of this ASU are effective for reporting periods beginning after December 15, 2017, with early adoption permitted. The adoptionprovisions of ASU No. 2016-15 is not expected to have a2016-01 on its financial statements. There was no material impact on the Company’sour financial statementsposition, results of operations, or related disclosures.cash flows.

 

In March 2016, the FASB issued ASU No. 2016-09,Improvements to Employee Share-Based Payment Accounting(“ASU 2016-09”). This standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods for public business entities. The method of adoption is dependent on the specific aspect of accounting addressed in this new guidance. Early adoption was permitted in any interim or annual period. ASU 2016-09 was adopted by the Company and did not have a material impact on the Company’s financial statements or related disclosures.

In February 2016, the FASB issued ASU No. 2016-02,Leases(“ASU 2016-02”). This standard amends various aspects of existing accounting guidance for leases, including the recognition of a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. This standard also introduces new disclosure requirements for leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years for public business entities. Early adoption iswas permitted, and the new standard must behad been adopted using a modified retrospective approach and provides for certain practical expedients.

On January 1, 2019, the Company adopted the new leasing standard and all related amendments. The Company is evaluatingelected the impact ofoptional transition method provided by the adoption ofFASB in ASU 2016-02 on2018-11, Leases (Topic 842): Targeted Improvements, and as a result, has not restated its condensed consolidated financial statements and related disclosures.


In January 2016, the FASB issued ASU No. 2016-01,Financial Instruments — Overall: Recognition and Measurement of Financial Assets and Financial Liabilities(“ASU 2016-01”). This standard affects the accounting for equity instruments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. ASU 2016-01 is effective in the first quarter of 2019. The Company is evaluating the impact of the adoption of ASU 2016-01 on its financial statements and related disclosures.

In November 2015, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update No. 2015-17,Balance Sheet Classification of Deferred Taxes, which eliminates the guidance in Topic 740, Income Taxes, that required an entity to separate deferred tax assets and liabilities between current and noncurrent amounts in a classified balance sheet. The amendments require that all deferred tax assets and liabilities of the same jurisdiction or a tax filing group, as well as any related valuation allowance, be offset and presented as a single noncurrent amount in a classified balance sheet. The standard became effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods, and may be applied on either prospectively to all deferred tax liabilities and assets or retrospectively to allprior periods presented. The Company has adopted this standard retrospectivelyelected the practical expedients upon transition to retain the lease classification and initial direct costs for all periods presented.any leases that existed prior to adoption. The Company has also not reassessed whether any contracts entered into prior to adoption of this standardare leases.

ASU 2016-02 did not have a material impact on the Company’s financial statements.Condensed Consolidated Statements of Comprehensive Income. The cumulative effect of the changes made to the Company’s Consolidated Balance Sheet as of January 1, 2019 for the adoption of the new leasing standard was as follows:

  Balance @
December 31, 2018
  Adjustment Due
to ASC 842
  Balance @
January 1,
2019
 
Right to Use Asset - Long Term    $87  $87 
             
Lease Liability – Long Term    $(87) $(87)

At September 30, 2019, the balance remaining in Right to Use Asset-Long Term and Lease Liability-Long Term was $29,000 and ($29,000) respectively.

 

The Company appliesdetermines if an arrangement is a more-likely-than-not recognition threshold for all tax uncertainties. Only those benefits that have a greater than fifty percent likelihoodlease at lease inception. Operating lease right-of-use (ROU) assets and operating lease liabilities are recognized based on the present value of being sustained upon examination by the taxing authorities are recognized. Based on its evaluation,future minimum lease payments over the lease term at commencement date. As most of the Company’s lease contracts do not include an implicit rate, the Company has concluded there are no significant uncertain tax positions requiring recognitionuses its incremental borrowing rate based on information available at commencement date in its financial statements.determining the present value of future payments. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in economic environments where the leased asset is located. The operating lease ROU asset also includes any initial direct costs and lease payments made prior to lease commencement and excludes lease incentives incurred.

 

The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company recognizes interest and/or penalties relatedhas certain lease agreements that contain both lease and non-lease components, which it has elected to uncertain tax positions in income tax expense. There are no uncertain tax positionsaccount for as of September 30, 2017 or December 31, 2016 and as such, no interest or penalties were recorded in income tax expense.a single lease component for all asset classes.

 

See Note 12, Commitments and Contingencies, for future minimum lease payments and maturities.


SENESTECH, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(In thousands, except share and per share data)

Note 2 - Summary of Significant Accounting Policies – (continued)

Accounting Standards Issued but Not Yet Adopted

In August 2014,2018, the FASB issued ASU No. 2014-15,Disclosuresauthoritative guidance intended to address a customer’s accounting for implementation costs incurred in a cloud computing arrangement that is a service contract. This guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance also requires presentation of Uncertainties about an Entity’s Ability to Continue as a Going Concern(“ASU 2014-15”). This standard requires management to perform an evaluation in each interim and annual reporting period whether there are conditions or events, consideredthe capitalized implementation costs in the aggregate,statement of financial position and in the statement of cash flows in the same line item that raise substantial doubt abouta prepayment for the entity’s ability to continue as a going concern within one yearfees of the dateassociated hosting arrangement would be presented, and the financial statements are issued. If such conditions or events exist, ASU 2014-14 also requires certain disclosuresexpense related to the capitalized implementation costs to be presented in the same line item in the statement of management’s plans and evaluation, as welloperations as the plans, if any, that are intended to mitigate those conditions or events that will alleviatefees associated with the substantial doubt. ASU No. 2014- 15hosting element (service) of the arrangement. This guidance is effective for the annual period ending after December 15, 2016 and for annual and interim periods thereafter. Early adoption was permitted for annual or interim reporting periods for which the financial statements have not been previously issued. ASU 2014-15 was adopted by the Company and did not have a material impact on the Company’s condensed consolidated financial statements or related disclosures.

In May 2014 the FASB issued ASU No. 2014-09,Revenue from Contracts with Customers. Since ASU 2014-09 was issued, several additional ASUs have been issued to clarify various elements of the guidance. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Adoption of the new standard is effective for reporting periods beginning after December 15, 2017.2019, including interim periods within those annual periods, with early adoption permitted. We plan to useare currently evaluating the modified retrospective method of adoption and will adopt the standard as of January 1, 2018, the beginning of our next fiscal year.. We have completed an initial evaluation of the potential impact from adopting the new standard, including a detailed review of performance obligations for all material revenue streams. Based on this initial evaluation, we do not expect adoption will have a material impact on our financial position, results of operations orand statement of cash flows. Related disclosures will be expanded in line with the requirements of the standard. We will continue our evaluation until ourflows upon adoption of this guidance. We do not expect this guidance to have a significant impact, or potential significant impact, to our unaudited condensed consolidated interim financial statements.

Other than the items noted above, there have been no new standard.accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our unaudited condensed consolidated interim financial statements.


Note 3 - Fair Value Measurements

 

The carrying amountsCompany issued common stock warrants to purchase shares of certaincommon stock in June of 2015 (see Note 9 — Stock-based Compensation for more details) that contain a cash settlement provision resulting in a common stock warrant liability that is revalued at the Company’s financial instruments, including cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. Assets and liabilities recordedend of each reporting period.

We value these warrant derivatives at fair value on a recurring basis in the balance sheets, as well as assets and liabilities measured at fair value on a non-recurring basis or disclosed at fair value, are categorized based upon the level of judgment associated with inputs used to measure their fair values.value. The accounting guidance for fair value, providesamong other things, establishes a consistent framework for measuring fair value and requires certain disclosures about howexpands disclosure for each major asset and liability category measured at fair value is determined.on either a recurring or nonrecurring basis. Fair value is defined as the price that would be received upon the sale ofto sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurementreporting date. The accounting guidance also establishesframework for measuring fair value consists of a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:

 

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;

 

Level 2—Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

 

Level 3—Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.

An asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques:

A.Market approach: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

B.Cost approach: Amount that would be required to replace the service capacity of an asset (replacement cost).

C.Income approach: Techniques to convert future amounts to a single present amount based upon market expectations, including present value techniques, option-pricing and excess earnings models.

 

The Company’s cash equivalents, which include money market funds,common stock warrant liabilities are classified as Level 13 because they are valued using quoted market prices. The Company’s marketable securities consist of held to maturity securities and are generally classified as Level 2 because their value is based on valuations using significant inputs derived from or corroborated by observable market data.

In certain cases where there is limited activity or less transparency around the inputs to valuation, securities are classified as Level 3. Level 3 liabilities consist of common stock warrant liability.valuation.


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 3 - Fair Value Measurements – (continued)

 

Items Measured at Fair Value on a Recurring Basis

 

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

 

  September 30, 2017 
  Level 1  Level 2  Level 3  Total 
Financial Assets:                
Money market funds $70  $  $  $70 
Corporate fixed income debt securities     2,949      2,949 
Total $70  $2,949  $  $3,019 
Financial Liabilities:                
Common stock warrant liability(1) $  $  $4  $4 
Total $  $  $4  $4 
September 30, 2019
Level 1Level 2Level 3Total
Financial Liabilities:
Common stock warrant liability (1)$$$

<1

$

<1

Total$$$<1$

<1

 

  December 31, 2016 
  Level 1  Level 2  Level 3  Total 
Financial Assets:                
None $  $  $  $ 
                 
Financial Liabilities:                
Common stock warrant liability(1) $  $  $69  $69 
Total $  $  $69  $69 
December 31, 2018
Level 1Level 2Level 3Total
Financial Assets:
Money market funds$$$$
Corporate fixed income debt securities
Total$$$$
Financial Liabilities:
Common stock warrant liability (1)$$$$
Total$$$$

 

(1) The change in the fair value of the common stock warrant and convertible notes payable for the three and nine months ended September 30, 2017 was recorded as a decrease to other income (expense) and interest expense of $30 and $69, respectively, in the statements of operations and comprehensive loss.

(1)There was no change (net) in the fair value of the common stock warrant for the three and nine months ended September 30, 2019. If there had been, it would have been recorded to other income (expense) and interest expense in the statements of operations and comprehensive loss.

 

Financial Instruments Not Carried at Fair Value

 

The carrying amounts of the Company’s financial instruments, including accounts payable and accrued liabilities, approximate fair value due to their short maturities. The estimated fair value of the convertible notes and other notes, not recorded at fair value, are recorded at cost or amortized cost which was deemed to estimate fair value.

 


SENESTECH, INC.Note 4 - Credit Risk

 

The Company is potentially subject to concentrations of credit risk in its accounts receivable. Credit risk with respect to receivables is limited due to the number of companies comprising the Company’s customer base. Although the Company is directly affected by the financial condition of its customers, management does not believe significant credit risks exist at September 30, 2019 or December 31, 2018. The Company does not require collateral or other securities to support its accounts receivable.


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

Note 4 - Investment in Securities Held to Maturity

As of September 30, 2017, investment in securities held to maturity primarily consisted of corporate fixed income securities and commercial paper. The Company did not have investments prior to the first quarter of 2017. The Company classifies all investments as held to maturity as these investments are short term, highly liquid investments which we intend to hold to maturity. Held to maturity securities are recorded at cost and gains and losses are only recognized as the sale or redemption of the securities is realized. Realized gains and losses are included in non-operating other income (expense) on the condensed statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the three and nine months ended September 30, 2017, the Company had a minimal amount of net realized gain (loss) on investments recorded. Interest and dividends on investments held to maturity are included in interest and other income, net, in the condensed statements of operations.

The following is a summary of held to maturity securities at September 30, 2017:

    September 30, 2017 
  Contractual
Maturity (in months)
 Cost  Gross Unrealized
Gains
  Gross Unrealized
Losses
  Fair Market
Value
 
Mutual funds   $  $  $  $ 
Corporate fixed income securities Less than 12 months  2,746   3      2,749 
Commercial paper Less than 12 months  200         200 
Total investments   $2,946  $3  $  $2,949 

 

Note 5 - Prepaid Expenses

 

Prepaid expenses consist of the following:

 

  September 30,
2017
  December 31,
2016
 
Director compensation $  $215 
Director, officer and other insurance  95   70 
Legal retainer  25   25 
Rent  17   17 
Inventory Purchase Deposits  20    
Engineering, software licenses and other  15   10 
Total prepaid expenses $172  $337 

16

SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

  September 30,  December 31, 
  2019  2018 
Director compensation $-  $100 
Director and officer insurance  161   121 
NASDAQ fees  14     
Legal retainer  25   25 
Marketing programs and conferences  54   53 
Professional services retainer  15   8 
Rent  -   19 
Equipment service deposits  2   3 
Foreign patent registration  22   - 
Engineering, software licenses and other  11   13 
Total prepaid expenses $304  $342 

 

Note 6 - Property and Equipment

 

Property and equipment, net consist of the following:

 

   September 30, December 31, 
 Useful
Life
 September 30,
2017
  December 31,
2016
    Useful Life 2019  2018 
Research and development equipment 5 years $1,335  $989    5 years $1,582  $1,552 
Office and computer equipment 3 years  672   235  (1) 3 years  753   742 
Autos 5 years  54   54 
Furniture and fixtures 7 years  34   17  7 years  37   37 
Autos/Trucks 5 years  306    
Leasehold improvements *  283   189  *  283   283 
    2,630   1,430     2,709   2,668 
Less accumulated depreciation and amortization    1,071   799     (1,879)  (1,585)
Total   $1,559  $631    $830  $1,083 

* Shorter of lease term or estimated useful life

 

(1)In August 2019, the Company disposed of computer equipment with a net book value of $2 resulting in a loss on the disposal of fixed assets of less than $1. In April and May 2019, the Company disposed of obsolete computer equipment with a net book value of $2 resulting in a loss on disposal of fixed assets of $2.

Depreciation and amortization expense was approximately $118$101 and $49$108 for the three months ended September 30, 20172019 and 2016,2018, respectively, and $272$314 and $143$332 for the nine months ended September 30, 20172019 and 2016,2018, respectively.

 

Note 7 - Accrued Expenses

 

Accrued expenses consist of the following:

 

 September 30, December 31, 
 September 30,
2017
  December 31,
2016
  2019  2018 
Compensation and related benefits $705  $82  $264  $479 
Accrued litigation  269   286 
Research project agreement  100    
Accrued Litigation  507   269 
Board Compensation  9   23 
Other     3   5    
Total accrued expenses $1,074  $371  $785  $771 

12

 

Note 8 - Accrued Contract Cancellation Settlement

The accrued contract cancellation settlement of $1,000 was the result of the Company entering into a settlement agreement with Neogen Corporation in which Neogen and the Company agreed to (a) terminate the existing Exclusive License Agreement between the Company and Neogen dated May 15, 2014 (the “License Agreement”), with neither Neogen or the Company having any further obligations thereunder (other than certain confidentiality obligations); (b) dismiss with prejudice the court action filed by Neogen in the District Court for the District of Arizona on January 19, 2017 (the “Court Action”); and (c) mutually release any and all existing or future claims between the parties and their affiliates related to or arising from the License Agreement or the Court Action. Under the terms of the agreement, the Company agreed to make a one-time payment in the amount of $1,000 in settlement of all claims and termination of all existing contracts between the parties. This payment was made in January, 2017. See Note 15 for further details.


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 98 - Borrowings

 

A summary of the Company’s borrowings, including capital lease obligations, is as follows:

 

 September 30, December 31, 
 September 30,
2017
  December 31,
2016
  2019  2018 
Short-term debt:             
Current portion of long-term debt  174   45   129   219 
Total short-term debt $174  $45  $129  $219 
Long-term debt:                
Capital lease obligations $290  $51  $175  $232 
Other unsecured promissory notes  521   132 
Other promissory notes  121   248 
Total  811   183   296   480 
Less: current portion of long-term debt  (174)  (45)  (129)  (219)
Total long-term debt $637  $138  $167  $261 

 

Capital Lease Obligations

 

Capital lease obligations are for computer and lab equipment leased through Great American,GreatAmerica Financial Services, Thermo Fisher Scientific, Navitas Credit Corp. and ENGS.ENGS Commercial Finance Co. These capital leases expire at various dates through June 2022. July 2023 and carry interest rates ranging from 6.4% to 11.6%.

Other Promissory Notes

Also included in the table above are three notes payable to Direct Capital, and one note to M2 Financing and one note to Fidelity Capital, all for the financing of fixed assets.

Note 10 - Notes Payable, Related Parties

A summary of the Company’s These notes payable, related parties is as follows:

  September 30,
2017
  December 31,
2016
 
Unsecured promissory note, interest rate of 4.25% and 8% per annum $18  $36 
Less: current portion of notes payable, related parties  18   30 
Total notes payable, long-term, related parties $  $6 

In April 2013, the Companyexpire at various dates through June 2022 and a previous employee entered into an agreementcarry interest rates ranging from 10.88% to settle all outstanding obligations consisting of a promissory note of $40, dated March 2009, and deferred salaries amounting to $72. The note and salary obligation continue to bear interest at 8% and 4.25%, respectively. The note requires monthly payments of $1 and matures in April 2018. The deferred salary obligation requires monthly payments of $1 and matures in May 2018.13.28%.

Amounts outstanding on these obligations were $18 and $36 at September 30, 2017 and December 31, 2016, respectively.

Interest expense on the notes payable, related parties, was $-0- and $1 for the three months and nine months ended September 30, 2017 and $56 for the year ended December 31, 2016 respectively.


TECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 119 - Common Stock Warrants and Common Stock Warrant Liability

 

The table summarizes the common stock warrant activity as of September 30, 20172019 as follows:

 

  Number          
  of  Date     Exercise 
Common  Stock Warrants Warrants  Issued  Term  Price 
Outstanding at December 31, 2015  610,487            
Initial Public Offering Underwriter  187,500  December 2016   5 years  $9.60 
Marketing and Development Services  100,000  February 2016   5 years(1)  $7.50 
Other Advisory Services  40,000  August 2016   3 years(1)  $7.50 
Promissory Notes  9,031  March 2016   3 years(1)  $7.50 
Warrants issued  336,531            
Warrants exercised  (117,733)           
Outstanding at December 31, 2016  829,285            
Warrants issued              
Warrants exercised              
Outstanding at September 30, 2017  829,285            
Common Stock Warrants Number
of
Warrants
  Date
Issued
 Term Exercise Price 
           
Outstanding at December 31, 2017  6,431,785         
             
Warrants issued  1,133,909  June 2018 5 Years $1.82 
Common Stock Offering Warrants Issued  5,357,052  August 2018 5 Years $1.15(1)
Common Stock Offering - Dealer Manager Warrants  267,853  August 2018 5 Years $1.725 
Warrants exercised  (1,475,659)        
Expired Warrants  (488,119)        
Outstanding at December 31, 2018  11,226,821         
Warrants issued  166,667  July 2019 5 Years $1.6875 
Warrants Exercised  (1,298,210) August 2018   $1.15 
Warrants Exercised  (312,000) August 2018   $0.95 
Outstanding at September 30, 2019  9,783,278         

 

(1)The common stock warrants also terminate, if not exercised by the earlier of (i) December 13, 2018, or the second anniversary of the closing ofissued in November 2017 with an initial public offeringexercise price of common stock; or (ii) a liquidation, dissolution or winding up of the Company.$1.50 per share adjusted downward to $0.95 per share effective July 24, 2018 in connection with our Rights Offering, and may be subject to further downward adjustments, pursuant to antidilution price adjustment protection contained within those warrants.

Promissory Notes; Common Stock Warrants

In conjunction with the issuance by the Company of certain promissory notes, the Company issued detachable common stock warrants (“Warrants”) to purchase an aggregate 270,400 shares of common stock, with an exercise price of $7.50 per share. The Warrants were exercisable until the earlier of (i) 5 years from the date of grant; (ii) December 13, 2018, or the second anniversary of the closing of our initial public offering; and (iii) the closing of liquidation, dissolution or winding up of the Company.

The Warrants have a net share settlement (cashless exercise) provision. With this provision the holder may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares based on the fair market value of the common stock at the time of exercise of the warrant after deduction of the aggregate exercise price. However, the Warrants would be exercised automatically in full pursuant to the net exercise provision, without any further action on behalf of the holder, immediately prior to the time the Warrants would otherwise terminate.

The Warrants are considered freestanding instruments as (i) they were transferred together with the notes issued but exist independently as a separate security; (ii) they may be exercised separately from the notes; and (iii) they are exercisable for a specific period (term) and do not impact the notes if and when exercised. 


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 119 - Common Stock Warrants and Common Stock Warrant Liability – (continued)

 

On November 21, 2017, the Company issued a total of 4,657,500 detachable common stock warrants issued with the second public offering of 5,860,000 shares of its common stock at $1.00 per share. The common stock warrant is exercisable until five years from the date of grant. The common shares of the Company’s stock and detachable warrants exist independently as separate securities. As such, the Company estimated the fair value of the common stock warrants, exercisable at $1.50 per share, to be $661 using a lattice model based on the following significant inputs: Common stock price of $1.00; comparable company volatility of 73.8%; remaining term 5 years; dividend yield of 0% and risk-free interest rate of 1.87. The initial exercise price of these warrants was $1.50 per share, which adjusted downward to $1.47 on July 24, 2018, the record date of the Right’s Offering and downward to $0.95 per share on August 13, 2018, the date of the Rights Offering, pursuant to antidilution price adjustment protection contained within these warrants. Per guidance of ASC 260, the Company recorded a deemed dividend of $333 on the 3,181,841 unexercised warrants that contained this antidilution price adjustment protection provision and was calculated as the difference between the fair value of the warrants immediately prior to downward exercise price adjustment and immediately after the adjustment using a Black Scholes model based on the following significant inputs: On July 24, 2018: Common stock price of $1.38; comparable company volatility of 72.4%; remaining term 4.33 years; dividend yield of 0% and risk-free interest rate of 2.83. On August 13, 2018: Common stock price of $1.02; comparable company volatility of 74.0%; remaining term 4.25 years; dividend yield of 0% and risk-free interest rate of 2.75.

On June 20, 2018, the Company entered into an agreement with a holder of 1,133,909 of the November 2017 warrants to exercise its original warrant representing 1,133,909 shares of Common Stock for cash at the $1.50 exercise price for gross proceeds of $1.7 million and the Company issued to holder a new warrant to purchase 1,133,909 shares of Common Stock at an exercise price of $1.82 per share. The new warrant did not contain the antidilution price adjustment protection that was contained within the exercised warrants. In June 2018, the Company recorded stock compensation expense of $1.7 million representing the fair value of the of 1,133,909 inducement warrants issued. The Company estimated the fair value of the Warrantscommon stock warrants, exercisable at issuance$1.82 per share, to be $1.7 million using a Black Scholes model based on the following significant inputs: Common stock price of $2.11; comparable company volatility of 72.6%; remaining term 5 years; dividend yield of 0% and risk-free interest rate of 2.8%. Also, in June 2018, an additional 341,750 of the November 8, 2017 warrants that were in the money at the time of exercise, were exercised for gross proceeds of $513.

On August 13, 2018, in connection with a Rights Offering of 5,357,052 shares of its common stock, the Company issued 5,357,052 warrants to purchase shares of its common stock at an exercise price of $1.15 per share. The Company estimated the fair value of the common stock warrants, exercisable at $1.15 per share, to be $3.6 million using a Monte Carlo option pricing model based on the following significant inputs: common stock price of $7.50 to $7.575;$0.94; comparable company volatility of 58.0%159.0%; remaining term 5 years; dividend yield of 0% and risk-free interest rate of 2.77%.

In connection with the closing of the Rights Offering, the Company issued a warrant to 76.7%; risk- free ratespurchase 267,853 shares of 1.31%common stock to 1.76%; andMaxim Partners LLC, an affiliate of the probabilitydealer-manager of an equity event occurring.the Rights Offering. The Company reflectedestimated the amounts recorded forfair value of the Warrants issued within stockholders’ deficit, as additional paid-in-capital. Although the Warrants are a derivative that can be net share settled, the Warrants are considered indexed to the Company’s common stock warrants, exercisable at $1.725 per share, to be $169 using a using a Monte Carlo model based on the following significant inputs: common stock price of $0.94; comparable company volatility of 159.0%; remaining term 5 years; dividend yield of 0% and the Company has the ability to settle the warrant contract in common shares and met the conditions within the contract to classify the Warrants as an equity instrument.risk-free interest rate of 2.77%.

 

Common Stock Warrant Issued for Marketing and Development Servicesto Underwriter of Common Stock Offering

In February 2016,July 2019, the Company issued to a stockholderH.C. Wainwright & Co., as placement agent, a warrant to purchase 100,000166,667 shares of common stock at an exercise price of $7.50$1.6875 per share as consideration for providing marketing and development services in Southeast Asia.connection with a common stock offering in July 2019. The warrant was fully vested and exercisable on the date of grant. The common stock warrant has the similar features as the Warrants discussed above, except it is exercisable until the earlier of (i) five years from the date of grant; (ii) December 13, 2018, or the second anniversary of the closing of our initial public offering of common stock; and (iii) the closing of a liquidation, dissolution or winding up of the Company. The Company estimated the fair value of the common stock warrant to be $431 on the date of grant using a Black- Scholes option pricing model based on the following significant inputs:common stock price of $7.57; comparable company volatility of 77.8%; remaining term 3.75 years; dividend yield of 0% and risk-free rate of 2.09%. The Company recorded the fair value of the warrant as stock-based compensation expense within general and administrative expense on the date of grant.

March 2016 Promissory Notes Common Stock Warrants

In March 2016, the Company issued certain unsecured notes with common stock warrants to purchase an aggregate of 9,032 shares of common stock at an exercise price of $7.50 per share. The common stock warrants are exercisable until the earlier of (i) three years from the date of grant; (ii) December 13, 2018, or the second anniversary of the closing of our initial public offering of common stock; and (iii) the closing of a liquidation, dissolution or winding up of the Company. The Company estimated the fair value of the common stock warrants on the date of grant using a Monte Carlo pricing model based on the following significant inputs: common stock price of $7.575; comparable company volatility 79.6%; and risk-free rate of 1.49%.

August 2016 Other Advisory Services

On August 16, 2016, the Company issued to each of two advisors warrants to purchase 20,000 shares of common stock at an exercise price of $7.50 per share as consideration for providing advisory services to the Company. The warrants were fully vested and exercisable on the date of grant until the earlier of (i) three years from the date of grant; (ii) December 13, 2018, or the second anniversary of the closing of our initial public offering of common stock; and (iii) the closing of a liquidation, dissolution or winding up of the Company. The Company recorded the fair value of the warrants as stock-based compensation expense within general and administrative expense on the date of grant.

Common Stock Warrant Issued to Initial Public Offering Underwriter

In December 2016, the Company issued to the underwriter of its IPO a warrant to purchase 187,500 shares of common stock at an exercise price of $9.60 per share as consideration for providing services in connection with the Company’s initial public offering. The warrant was fully vested and exercisable on the date of grant.issuance. The common stock warrant is exercisable until five years from the date of grant. The Company estimated the fair value of the common stock warrantwarrants, exercisable at $1.6875 per share, to be $939 on the date of grant$127 using a Black- Scholes option pricinglattice model based on the following significant inputs:commoninputs: Common stock price of $8.00;$1.34; comparable company volatility of 82.1%133.3%; remaining term 5 years; dividend yield of 0% and risk-free interest rate of 1.92%2.07%.


SENESTECH, INC.

 

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

Note 11 - Common Stock Warrants and Common Stock Warrant Liability – (continued)

University of Arizona Common Stock Warrant

 

In connection with the June 2015 amended and restated exclusive license agreement with the University of Arizona (“University”), the Company issued to the University a common stock warrant to purchase 15,000 shares of common stock at an exercise price of $7.50 per share. The warrant was fully vested and exercisable on the date of grant, and expires, if not exercised, five years from the date of grant. In the event of a “terminating change” of the Company, as defined in the warrant agreement, the warrant holder would be paid in cash the aggregate fair market value of the underlying shares immediately prior to the consummation of the terminating change event. Due to the cash settlement provision, the derivative warrant liability was recorded at fair value and is revalued at the end of each reporting period. The changes in fair value are reported in other income (expense) in the statements of operations and comprehensive loss. The estimated fair value of the derivative warrant liability was $53 at the date of grant.

 

The estimated fair value of the derivative warrant liability was $4$0 at September 30, 2017.2019. As this derivative warrant liability is revalued at the end of each reporting period, the fair values as determined at the date of grant and subsequent periods werewas based on the following significant inputs using a Monte Carlo option pricing model: common stock price of $7.91; comparable company volatility of 77.7% of the underlying common stock; risk-free rates of 1.93%; and dividend yield of 0%; including the probability assessment of a terminating change event occurring. The change in fair value of the derivative warrant liability was $65($0) and $0 for the three and nine months ended September 30, 2017 and2019. As such, no entry was recorded in other income (expense) in the accompanying statements of operations and comprehensive loss.


SENESTECH, INC.

July 2015 Consulting Agreement Common Stock WarrantNOTES TO CONDENSED FINANCIAL STATEMENTS

(In July 2015, the Company issued a common stock warrant to purchase 121,227 shares of common stock, with an exercise price of $7.50thousands, except share and per share as consideration for services under a consulting arrangement. The warrant was fully vested and exercisable on the date of grant. This common stock warrant has the similar features as the Warrants described above, except it is exercisable until the earlier of (i) ten years from the date of grant; (ii) December 13, 2018, the second anniversary of the closing of our initial public offering of common stock; and (iii) the closing of a liquidation, dissolution or winding up of the Company. The estimated the fair value of the common stock warrant on the date of grant was $537 as determined by using a Black-Scholes option pricing model based on the following significant inputs: common stock price of $7.575; comparable company volatility of 60.9%; expected term of 6.25 years; risk-free rate of 2.09%; and dividend yield of 0%. The Company recorded the fair value of the warrant as stock-based compensation expense within general and administrative expense in the accompanying statements of operations and comprehensive loss in 2015.data)

Northern Arizona University Common Stock Warrant

In November 2015, the Company issued a common stock warrant to purchase 210,526 shares of common stock at an exercise price of $15.00 per share to Northern Arizona University (“NAU”) as part of the consideration given with the Series A convertible preferred stock in exchange for the full cancellation of a promissory note that had been previously issued to NAU.

 

Note 1210 - Stockholders’ Deficit

 

Capital Stock

The Company was organized under the laws of the state of Nevada on July 27, 2004 and was subsequently reincorporated under the laws of the state of Delaware on November 10, 2015. In connection with the reincorporation, as approved by the stockholders, the Company changed its authorized capital stock to consist of (i) 100 million shares of common stock, $.001 par value, and (ii) 2 million shares of preferred stock, $0.001 par value, designated as Series A convertible preferred stock. In December 2015, the Company amended its Certificate of Incorporation to change its authorized capital stock to provide for 15 million authorized shares of preferred stock of which 7,515,000 was designated as Series B convertible preferred stock, par value $.001 per share.

Common Stock

 

The Company had 10,363,18928,288,285 and 10,157,29223,471,999 shares of common stock issued and outstanding as of September 30, 20172019 and December 31, 2016,2018, respectively. 

 

During the nine months ended September 30, 2017,2019, the Company issued an aggregate of 205,8974,816,286 shares of common stock as follows: 48,240 shares to consultants for services, valued at $137, to settle previous claims; 14,014 shares for the cashless exercise of vested stock options; and 143,643 shares for net settlement of restricted stock units that vested during the period.

 


an aggregate of 3,037,038 shares in connection with a public offering generating net proceeds to the Company of approximately $3.6 million, as further described below
an aggregate of 1,610,210 shares for the exercise of outstanding warrants for gross proceeds of $1.8 million (see Note 9 — Common Stock Warrants and Common Stock Warrant Liability for further details)
An aggregate of 105,474 shares for service as a result of the vesting of restricted stock units
3,022 shares for the exercise of stock options
21,962 shares for the cashless exercise of stock options and
an aggregate of 38,580 shares to certain employees in net settlement of bonus compensation totaling $32.

Rights

Public Offering

 

In April 2016,On July 16, 2019, the Company offered to the existing holders of shares of (i) its common stock and (ii) Series B convertible preferred stock, in each case, as of April 8, 2016 (the “Record Date”), at no charge, non-transferable subscription rights, on a pro rata basis, to purchaseissued 3,037,038 shares of common stock, including 696,296 shares to the Company’s chief executive officer and 7,408 shares to an employee of the Company, in a public offering of shares of the Company’s common stock at a subscription price of $2.50$1.35 per share, (the “Rights Offering”).resulting in net proceeds of approximately $3.6 million after deducting certain fees due to the placement agent and other transaction expenses. In addition, the holders also had the rightCompany issued a warrant to purchase additional166,667 shares of common stock, if any shares remain unsubscribed. The Company offered subscription rights on 5,794,162 shares of its common stock. The Rights Offering was conducted as a private placement on a “best efforts” basis, with no minimum subscription required.

The subscription rights were initially exercisable beginning on April 8, 2016 and expiring on April 29, 2016 (the “Subscription Period”). However, the Company reserved the right to extend the Subscription Period for up to two additional weeks. The Company extended the Subscription Period for one additional week. The Rights Offering closed on May 6, 2016.

The Company issued 2,478,486 shares of common stock and received aggregate consideration of $6,199 in the Rights Offering. The aggregate consideration received consisted of: (i) $5,284 in cash; (ii) $821 in consideration paid through the cancellation of $821 in outstanding principal amount (and related unpaid interest) under certain outstanding unsecured notes; and (iii) the extinguishment of $94 in amounts owed by the Company for services and related miscellaneous expenses. Such cash proceeds will be used for working capital and general corporate purposes. As the Rights Offering was offered to certain existing holders of the Company’s common stock to the shares sold are treated as outstanding from the dateplacement agent at an exercise price of their issuance in the computation of loss$1.6875 per share, basic and diluted in future periods.share.

 

Note 1311 - Stock-based Compensation

 

Effective December 2008, the Company established the 2008 – 2009 Non-Qualified Stock Option Plan (the “2008 – 2009 Plan”) under which no stock options remain outstanding at September 30, 2017. The stock-based awards were issued with a price not less than $15.00 per share or 100% of the fair value of a share of common stock on the date of grant. After July 2015, no further awards were granted under the 2008 – 2009 Plan.

Effective July 2015,On June 12, 2018, the Company’s stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”) to replace the Company’s 2015 Equity Incentive Plan (the “2015 Plan”), which permits. The 2018 Plan authorizes the issuance of up to 2,000,000 shares reserved for the grant of stock options, stock appreciation rights, restricted stock units and other stock-based awards for employees, directors or consultants of the Company. The Board of Directors and the Company’s stockholders approved an additional 1,000,000 shares of our common stock. In addition, up to 2,874,280 shares of our common stock reserved for issuance under the 2015 Plan. The stock-basedPlan became available for issuance under the 2018 Plan to the extent such shares were available for issuance under the 2015 Plan as of June 12, 2018 or cease to be subject to awards outstanding under the 2015 Plan, such as by expiration, cancellation, or forfeiture of such awards.

Stock options are generally issued with aan exercise price equal to no less than fair value at the date of grant. Options granted under the 20152018 Plan generally vest immediately, or ratably over a two- to 36-month period coinciding with their respective service periods; however, participants may exercise their options prior to vesting as provided by the 20152018 Plan. Unvested shares issued for optionoptions exercised early may be subject to a repurchase by the Company if the participant terminates, at the original exercise price. Options under the 20152018 Plan generally have a contractual term of five or ten years. Certain stock option awards provide for accelerated vesting upon a change in control.

As of September 30, 2017,2019, the Company had 779,095632,936 shares of common stock available for issuance under the 20152018 Plan.

 

The Company measures the fair value of stock options with service-based and performance-based vesting criteria to employees, directors and consultants on the date of grant using the Black-Scholes option pricing model. The fair value of equity instruments issued to non-employees is re-measured as the award vests. The Black-Scholes valuation model requires the Company to make certain estimates and assumptions, including assumptions related to the expected price volatility of the Company’s stock, the period under which the options withwill be outstanding, the rate of return on risk-free investments, and the expected dividend yield for the Company’s stock.


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 1311 - Stock-based Compensation - (continued)

 

The weighted-average assumptions used in the Black-Scholes option-pricing model used to calculate the fair value of options granted during the nine months ended September 30, 2017,2019 were as follows:

 

  Employee Non-Employee
Expected volatility 73.8% -83.776.4%-80.6 % N/A
Expected dividend yield  N/A
Expected term (in years) 3.0 to 3.53.0-6.0 N/A
Risk-free interest rate 1.45%-1.941.63% -2.48 % N/A

The weighted average grant date fair value of options granted during the nine months ended September 30, 2019 was $1.29 per share, as per the table below.

 

Due to the Company’s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption was determined based on historical volatilities from traded options of biotech companies of comparable in size and stability, whose share prices are publicly available. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. The expected term of options granted to employees is calculated based on the mid-point between the vesting date and the end of the contractual term according to the simplified method as described in SEC Staff Accounting Bulletin 110 because the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its awards have been outstanding. For non-employee options, the expected term of options granted is the contractual term of the options. The risk-free interest rate is determined by reference to the implied yields of U.S. Treasury securities with a remaining term equal to the expected term assumed at the time of grant. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends.

 

The following table summarizes the stock option activity, for both equity plans, for the periods indicated as follows:

 

  Number of
Options
  Weighted
Average
Exercise
Price Per
Share
  Weighted
Average
Remaining
Contractual
Term
(years)
  Aggregate
Intrinsic
Value(1)
  Number of
Options
  Weighted
Average
Exercise
Price Per
Share
  Weighted
Average
Remaining
Contractual
Term
(years)
  Aggregate
Intrinsic
Value (1)
 
Outstanding at December 31, 2016   1,477,300   1.61   5.8  $9,662 
Outstanding at December 31, 2018  1,721,771  $1.57   4.0  $ 
Granted   161,500  $8.04   5.0  $   1,167,906  $1.29   4.9  $ 
Exercised   (15,000) $0.50         (63,990) $0.65     $ 
Forfeited     $         (59,500) $     $ 
Expired   (65,000) $10.22         (18,510) $     $ 
Outstanding at September 30, 2017   1,558,800   1.73   5.1  $183 
Exercisable at September 30, 2017   1,263,599  $1.08   4.8  $968 
Outstanding at September 30, 2019  2,747,677  $1.40   3.9  $ 
Exercisable at September 30, 2019  1,667,064  $1.55   2.8  $ 

 

(1)The aggregate intrinsic value onin the table was calculated based on the difference between the estimated fair market value of the Company’s stock and the exercise price of the underlying option.options. The estimated stock values used in the calculation was $1.85$1.01 and $8.15$0.59 per share atfor the nine months ended September 30, 20172019 and the year ended December 31, 2016,2018, respectively.


SENESTECH, INC.Restricted Stock Units

 

The following table summarizes restricted stock unit activity for the nine months ended September 30, 2019:

  Number of
Units
  Weighted Average
Grant-Date Fair
Value Per Unit
 
Outstanding as of December 31, 2018  136,245  $0.98 
Granted  123,727  $1.51 
Vested  (142,507) $1.10 
Forfeited    $ 
Outstanding as of September 30, 2019  117,465  $1.42 

SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 1311 - Stock-based Compensation – (continued)

 

The stock-based compensation expense was recorded as follows:

 

 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 
 Three Months Ended September 30 Nine Months Ended September 30,  2019  2018  2019  2018 
 2017 2016 2017 2016          
Research and development $85 135 $269 $309  $1  $29  $11  $87 
General and administrative  861  798  2,549  2,097   203   326   664   3,003 
Total stock-based compensation expense $946  933 $2,818 $2,406  $204  $355  $675  $3,090 

 

The allocation between research and development and selling, general and administrative expense was based on the department and services performed by the employee or non-employee.

 

At September 30, 2017,2019, the total compensation cost related to non-vestedrestricted stock units and unvested options not yet recognized was $1,942,$1,205, which will be recognized over a weighted average period of four years,36 months, assuming the employees and non-employees complete their service period required for vesting.

Effective December 2008, the Company established the 2008-2009 Plan under which no stock options remain outstanding at September 30, 2017. The stock-based awards were issued with a price not less than $15.00 per share or 100% of the fair value of a share of common stock on the date of grant. After July 2015, no further awards were granted under the 2008 – 2009 Plan.

Restricted Stock Units

The following table summarizes restricted stock unit activity for the nine months ended September 30, 2017:

   Number of
 Units
  Weighted
Average
Grant-Date Fair
Value Per Units
 
Outstanding as of December 31, 2016   455,430  $0.76 
Granted   117,885(1) $6.95 
Vested   (228,333) $2.00 
Forfeited     $ 
Outstanding as of September 30, 2017   344,982(2) $2.05 

(1)40,000 restricted stock units were granted on March 27, 2017 with a weighted average grant date fair value of $8.35, 17,885 restricted stock units were granted on May 19, 2017 with a weighted average grant date fair value of $6.99 and 60,000 restricted stock units were granted on June 19, 2017 with a weighted average grant date fair value of $6.00.

(2)At September 30, 2017, the total compensation cost related to non-vested restricted stock units not yet recognized was $1,075, which will be recognized over a weighted average period of 1.3 years, assuming the recipients complete their service period required for vesting.

24

SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

Note 14 - License and Other Agreements

Neogen Corporation

In May 2014, the Company entered into an exclusive license agreement with Neogen Corporation (“Neogen”). The Company granted an exclusive license to Neogen to (i) use the Company’s intellectual property (“IP”), consisting primarily of the ContraPest technology and (ii) manufacture, distribute and sell commercial rodent control products in the United States and certain U.S. territories, Canada and Mexico.

As previously disclosed in our Current Report on Form 8-K dated and filed January 23, 2017, on January 23, 2017 we entered into a termination agreement (the “Settlement Agreement”) with Neogen Corporation (“Neogen”). Pursuant to the Settlement Agreement, the parties agreed to (a) terminate the existing Exclusive License Agreement between us and Neogen dated May 15, 2014 (the “License Agreement”), with neither Neogen or us having any further obligations thereunder (other than certain confidentiality obligations); (b) dismiss with prejudice the court action filed by Neogen in the District Court for the District of Arizona on January 19, 2017 (the “Court Action”), as further described below; and (c) mutually release any and all existing or future claims between the parties and their affiliates related to or arising from the License Agreement or the Court Action. As part of the Settlement Agreement, we agreed to pay to Neogen upon the execution of the Settlement Agreement an aggregate of $1,000 in settlement of all claims.

For the nine months ended September 30, 2017 and the year ended December 31, 2016, the Company recognized revenue of $0 and $186, respectively, under the License Agreement.

Bioceres/INMET S.A. Agreement

In January 2016, the Company entered into a services agreement with Bioceres, Inc. (“Bioceres”), a wholly-owned subsidiary of Bioceres S.A., a leading agricultural biotechnology company in Argentina, and its Argentinean subsidiary, Ingenieria Metabolica S.A. (“INMET”) to develop a production method for synthetic triptolide, the main ingredient in ContraPest. The Company also entered into an agency agreement with INMET whereby the Company appointed INMET as its exclusive agent to seek regulatory approval for and conduct pre-sales and marketing of its product, ContraPest, in Argentina. The Company and INMET have also agreed to manufacture and distribute its product in Argentina and other countries, as mutually agreed, through a newly formed entity.

The term of the service agreement is for two years. The service agreement can be terminated at any time upon written notice by either party for any reason. The term of the agency agreement with INMET is the earlier of: (i) when the Company and INMET incorporate the joint venture entity in Argentina or (ii) January 2018.

At September 30, 2017, the Company had accrued expenses of $100 due to Bioceres as detailed in the table or accrued expenses in Note 7


SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 1512 - Commitments and Contingencies

 

Legal Proceedings

 

The Company may be subject to legal proceedings and claims arising from contracts or other matters from time to time in the ordinary course of business. Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its financial position, results of operations or liquidity.

 

Neogen Settlement AgreementOn February 20, 2018, New Enterprises, Ltd. (“New Enterprises”), filed a lawsuit against the Company and Roth Capital Partners, LLC (“Roth”) in the U.S. District Court for the District of Arizona (the “Court”). The complaint alleges nine counts against the Company, including that the Company: engaged in common law fraud and securities fraud to induce the chairman of New Enterprises into investing in the Company; failed to register New Enterprises’ requested transfer; breached stock certificates and the lock-up contract; tortuously interfered with prospective business advantage; and was liable for conversion. New Enterprises is seeking monetary damages, including compensatory damages, punitive damages, and attorney’s fees. On December 3, 2018, the Court issued its order granting the Company’s and Roth’s motions to dismiss all of New Enterprises’ claims but gave them leave to file a motion to amend the complaint. On January 25, 2019, New Enterprises moved for leave to file an amended complaint, alleging similar claims against the Company and Roth, and the court granted that motion. On April 5, 2019, New Enterprises filed an amended complaint, alleging similar claims against the Company and Roth. The Company and Roth moved to dismiss the amended complaint, and on August 16, 2019, the Court issued its order denying the Company’s and Roth’s motions to dismiss. Roth has made a claim for indemnification to the Company based on contractual indemnification agreements, but to date the Company has not accepted Roth’s indemnification demand.

 

See Note 14 aboveOn April 20, 2018, the Company’s former Executive Vice President and Chief Operating Officer Andrew Altman filed a charge of employment discrimination with regardsthe Equal Employment Opportunity Commission (EEOC) against the Company. Mr. Altman claimed that he was terminated after he expressed opposition to an email that Cheryl Dyer, Chief Research Officer, had sent out to the Settlement Agreement with Neogen.management team, in which she criticized a Mormon newspaper. The Company filed a position statement on May 21, 2018. No substantive action has been taken since then, and the Company has not heard anything further either from the EEOC or Mr. Altman’s attorneys.

 

Although noticeLease Commitments

The Company is obligated under capital leases for certain research and computer equipment that expire on various dates through July 2023. At September 30, 2019, the gross amount of office and computer equipment, and research equipment and the related accumulated amortization recorded under the capital leases was $498 and $252, respectively.

In February 2012, the Company entered into an operating lease for its corporate headquarters. The lease was due to expire in January 2015. In December 2013, the Company amended its lease to expand into the remaining area in the building and extended the term to December 31, 2019. In February 2014, the Company further amended the lease to expand into an adjacent building. The lease requires escalating rental payments over the lease term. Minimum rental payments under the operating lease are recognized on a straight-line basis over the term of the legal action by Neogenlease and accordingly, the Company records the difference between the cash rent payments and the Settlement Agreement with Neogen, occurred after December 31, 2016,recognition of rent expense as pera deferred rent liability. The lease is guaranteed by the provisions of Accounting Standards Codification Topic 450 Loss Contingencies, included in the financial statementsPresident of the Company at December 31, 2016 is a $1,000 chargeCompany. We are currently in discussions to general and administrative expenses and a corresponding accrual of contract cancellation settlement agreement related to this agreement.extend the current lease.

 


17

SENESTECH, INC.

 

SENESTECH, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

 

Note 1512 - Commitments and Contingencies – (continued)

 

ResolutionOn November 16, 2016, we leased an additional 1,954 square feet of Disputeresearch and development space, also in Flagstaff. This lease expired on November 15, 2018 but was extended for an additional 24 months, through November 2020. A subsequent amendment to the lease allows for the Company to cancel the lease at any time through the lease term with 30-day notice. In June 2019, the Company cancelled approximately 1,000 square feet of this leased space, and the fixed rental payment was reduced for the remaining term of the lease. The lease extension requires fixed rental payments over the lease term. Minimum rental payments under the operating lease are recognized on a straight-line basis over the term of the lease as expense, and accordingly, the Company recorded no deferred rent liability under this lease.

 

In recognition of his continued support and cooperation, and to resolve a dispute regarding whether his options appropriately expired in the first quarter of 2016, in July 2016, the Company’s Board of Directors agreed to issue to its former chief executive officer 120,000 shares of the Company’s common stock. The expense of $300 associated with this full and final settlement was recorded at December 31, 2016.

Lease Commitments

RentTotal rent expense was $246$187 and $234$183 for the nine months ended and year ended September 30, 20172019 and December 31, 2016,September 30, 2018, respectively. The future minimum lease payments under our non-cancellable operating lease and future minimumour capital lease payments as of September 30, 20172019 are as follows:

 

 Capital
Leases
 Operating
 Lease
  Capital
Leases
  Operating
Lease
 
Years Ending December 31,          
2017 $25 $63 
2018 96 258 
2019 88 221   24   62 
2020 67    78   24 
2021  84     63    
2022  33    
2023  3     
Total minimum lease payments $360 $542  $201  $86 

 

 Capital
Leases
  Capital
Leases
 
Less: amounts representing interest (ranging from 7.25% to 11.56%) $75 
   
Less: amounts representing interest (6.39%, ranging from 10.48% to 11.56%) $26 
       
Present value of minimum lease payments 285   175 
       
Less: current installments under capital lease obligations  70   70 
       
Total long-term portion $215  $105 

 

Note 1613 - Subsequent Events

  

In October of 2017,On November 1, 2019, the Company net issued 26,308311 shares of its common stock to two executivesin satisfaction of the Company in net settlementa cashless exercise of restrictedvested common stock units that vested on September 30, 2017 but were not issued until October 2, 2017.options.

 

The Company has evaluated subsequent events from the balance sheet date through November 14, 2019, the date at which the financial statements were issued, and determined that there were no other items that require adjustment to or disclosure in the financial statements.


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

As used in this Quarterly Report on Form 10-Q, “SenesTech,” the “Company,” “we,” “us,”“us” or “our” and “the Company” refer to SenesTech, Inc., a Delaware corporation.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our condensed consolidated financial statements and related notes.

Forward-Looking Statements

Some statements and information contained in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, notes to our condensed consolidated financial statements and elsewhere in this Quarterly Report on Form 10-Qreport are not historical facts but are forward-lookingforward- looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, readers can identify forward-lookingforward- looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “intend,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or the negative of these terms or other comparable terminology, which when used are meant to signify the statement as forward-looking. These forward-looking statements include, but are not limited to, our expectations, assumptions and estimates regarding new and current accounting and tax standards and policies; our expectations and plans regarding our operating plan, including operating expenses, product sales and revenue expectations, profitability and cash flows; anticipated financing; our beliefs regarding our revenue targets and the sufficiency of our liquidity and capital resources; possible outcomes of ongoing litigation; our ongoing and planned commercialization of ContraPest and product development of our other product candidates; our expectations regarding regulatory approval of our products or product candidates; and statements about our plans, objectives, expectations and intentions and other statements that are not historical facts. Specific examples of forward-looking statements include those concerning the sufficiency of our cash and future revenue to fund operations, our expectations as to expenses, future revenue and the commercialization of our products, our research and development plans and initiatives and the development of our products. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and situations that are difficult to predict and that may cause our own, or our industry’s actual results, to be materially different from the future results that are expressed or implied by these statements. Accordingly, actual results may differ materially from those anticipated or expressed in such statements as a result of a variety of factors, including those discussed in Item 1A of Part III of our Annual Report on Form 10-K, as amended by Form 10-K/A, for the year ended December 31, 20162018, both filed with the SEC on March 29, 2019 (collectively, the “2018 Annual Report”), entitled “Risk Factors,” and those contained from time to time in our other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

All amounts shown in the following Management’s Discussion and Analysis of Financial Condition and Results of Operations are full amounts (and are not shown in thousands).

Overview

 

Since our inception, in 2004, we have devoted substantially allsustained significant operating losses in the course of our resources to organizing and staffing our company, conducting research and development and commercialization activities and expect such losses to continue for our product candidates, business planning, raising capital and acquiring and developing product and technology rights. Until August 2016, we did notthe near future. We have any products approved for sale, and we have not generated any significantlimited revenue to date from product sales, research grants and licensing fees received under our former license agreement with Neogen. In 2017, we began to date.prepare and launch commercialization of our first product, ContraPest. We have primarily funded our operations to date with proceeds fromthrough the sale of equity securities, including convertible preferred stock, common stock and preferred stock, the warrants to purchase common stock. Public equity sales include:

(i)an initial public offering of 1,875,000 shares of our common stock at $8.00 per share for gross proceeds of $15 million on December 8, 2016 with warrants to purchase an additional 187,500 shares issued to Roth Capital Partners, LLC with an exercise price of $9.60 per share, as underwriter,

(ii)a public offering on November 21, 2017 of 5,860,000 shares of our common stock at $1.00 per share for gross proceeds of $5.9 million, with warrants issued to investors to purchase an additional 4,657,500 shares of our common stock with an initial exercise price of $1.50 per share that subsequently adjusted downward to $0.95 per share pursuant to antidilution price protection contained within those warrants, and warrants issued to Roth Capital Partners, LLC, as underwriter, to purchase an additional 945,000 shares with an exercise price of $1.50 per share,

(iii)a private placement of warrants to purchase 1,133,909 shares of common stock in June 2018 with an exercise price of $1.82 per share for gross proceeds of $2.1 million, in connection with an inducement agreement with a holder of outstanding warrants issued in November 2017 to exercise its original warrant representing 1,133,909 shares at an exercise price of $1.50 per share,

(iv)a rights offering in August 2018 (the “Rights Offering”), where we accepted subscriptions for 5,357,052 units for a purchase price of $1.15 per unit for gross proceeds of $6.2 million, with each unit consisting of one share of our common stock and one warrant, with each warrant exercisable for one share of our common stock at an exercise price of $1.15 per share, and warrants issued to an affiliate of Maxim Group, LLC, as dealer-manager, to purchase an additional 267,853 shares at $1.725 per share,


(v)issuance of 312,000 shares and 1,266,399 shares of common stock as a result of the exercise of warrants during the nine months ended September 30, 2019 at an exercise price of $0.95 and $1.15 per warrant, respectively for gross proceeds of $1.8 million, and
(vi)issuance of 3,037,038 shares of common stock at $1.35 per share for gross proceeds of $4.1 million, in a public offering on July 16, 2019, with warrants to purchase an additional 166,667 shares issued to H.C. Wainwright & Co. with an exercise price of $1.6875 per share, as placement agent for the public offering.

We have also raised capital through debt financing, consisting primarily of convertible and other promissory notesnotes; and, to a lesser extent, payments received in connection with product sales, research grants and licensing fees.

Through September 30, 2017,2019, we had received net proceeds of $49.2$67.2 million from our sales of common stock, preferred stock and warrant exercises and issuance of convertible and other promissory notes, an aggregate of $1.7 million from licensing fees and an aggregate of $1.6$0.5 million from research grantsin net product sales. At September 30, 2019, we had an accumulated deficit of $93.1 million and licensing fees.cash and cash equivalents of $3.9 million.

 

We have incurred significant operating losses every year since our inception. Our net losses were $2.9 million, $10.0$2.6 million and $11.0$7.2 million for the three and nine months ended September 30, 20172019 and $2.5 million and $9.3 million for the yearthree and nine months ended December 31, 2016, respectively. As of September 30, 2017, we had an accumulated deficit of $71.3 million.2018, respectively. We expect to continue to incur significant expenses and generate operating losses for at least the next 12 months.

 

We have historically utilized, and intend to continue to utilize, various forms of stock-based awards in order to hire, retain and motivate talented employees, consultants and directors and encourage them to devote their best efforts to our business and financial success. In addition, we believe that our ability to grant stock-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders.

 

As a result, a significant portion of our operating expenses includes stock-based compensation expense. Stock-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in our business and an important part of our compensation strategy. Specifically, our stock-based compensation expense for each of the three and nine months ended September 30, 20172019 was $204,000 and September 30, 2016 was $2.8 million and $2.4 million, respectively,$675,000, which represented 28.1%7.8% and 33.0%9.3%, respectively, of our total operating expenses for those periods and $355,000 and $3.1 million for the same periods in 2018, which represented 14.3% and 33.4%, respectively, of our total operating expenses for those periods. .

 

Our ultimate success depends upon the outcome of a combination of factors, including: (i) successful commercialization of ContraPest and maintaining and obtaining regulatory approvals of our products and product candidates, (ii) market acceptance, commercial viability and profitability of ContraPest and other products; (iii) our ability to market our products and establish an effective sales force and marketing infrastructure to generate significant revenue; (iv) the success of our research and development; (v) our ability to retain and attract key personnel to develop, operate and grow our business; and (vi) our ability to meet our working capital needs.

Based upon our current operating plan, we expect that cash and cash equivalents at September 30, 2019, in combination with anticipated revenue and any additional sales of our equity securities, will be sufficient to fund our current operations for at least the next six months. We have taken and will continue to take actions to reduce our operating expenses and to concentrate our resources toward the successful commercialization of ContraPest in the U. S. However, if anticipated revenue targets and margin targets are not achieved and we are unable to raise necessary capital through the sale of our securities, we may be required to take other measures that could impair our ability to be successful and operate as a going concern. In any event, we are likely to require additional capital in order to fund our operating losses and research and development activities until we become profitable. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to need to raise capital through equity or debt financing. If such equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate commercialization and development efforts.

Components of our Results of Operations

 

RevenueNet Sales

 

To date, we have generated $34,000, from productNet sales are comprised primarily of sales, net of discounts and we expectpromotions, of ContraPest and related components, to generate increased revenue from the sale of products or royalties in the fourth quarter of 2017. Except for the minimal product sales noted above, all our revenue to date has been derived from payments received in connection with research grantsdistributors and licensing fees received as a result of our execution of the former license agreement with Neogen.

customers. 


We recognized product sales revenue of $17,000 and $-0- for the three months ended September 30, 2017 and 2016, respectively, and $34,000 and $-0- and for the nine months ended September 30, 2017 and 2016, respectively. In addition, for the nine months ended September 30, 2016, we recognized revenue of $139,000 under our former license agreement with Neogen and $122,000 under NIH grants. We do not anticipate additional grant revenue under the NIH grants or additional revenue from our former license agreement with Neogen.

Operating Expenses

 

Research and Development Expenses

 

Research and development expenses consist primarily of costs incurred in connection with the discoveryresearch and development of ContraPest and our other product candidates, which include:

 

Employee-relatedEmployee related expenses, including salaries, related benefits, travel and stock-based compensation expense for employees engaged in research and development functions;

 

Expenses incurred in connection with the development of our product candidates; and

 

Facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and supplies.

 

We expense research and development costs as incurred.

 

We also continue to develop our supply chain, particularly identifying and improving our sourcing of key ingredients for our product candidates. At this time, we cannot reasonably estimate the costs for completing thefurther development of ContraPest or the cost associated with the development of any of our other product candidates.supply chain.

 

We plan to continue to hire employees to support our research and development efforts and anticipate that we will continue to utilize various forms of stock-based compensation awards in order to attract and retain employees for our research and development efforts. As a result, we anticipate that stock-based compensation expense will continue to represent a significant portion of our research and development expenses for the foreseeable future.

Selling, General and Administrative Expenses

 

GeneralSelling, general and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance, sales, marketing and administrative functions. GeneralSelling, general and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, consulting, accounting, contract sales expenses and audit services.

 

We anticipate that our selling, general and administrative expenses may increase in the future as we increase our headcount to support commercialization of any approved productsContraPest and further development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance costs as well as investor and public relations expenses associated with being a public company.

 

We plan to continue to hire employees to support our commercialization of any approved products and further development of our product candidates, and anticipate that we will continue to utilize various forms of stock-based compensation awards in order to attract and retain qualified employees. As a result, we anticipate that stock-based compensation expense will continue to represent a significant portion of our general and administrative expenses for the foreseeable future.Interest Income

 

Other Income (Expense), Net

Interest Income. Interest income consists primarily of interest income earned on cash and cash equivalents. Our interest income has not been significant due to nominal cash and investment balances and low interest earned on invested balances.

 


Interest Expense.

Interest expense in 2017 consists primarily of interest accrued on our capital lease and note commitments. Interest expense in 2016 consisted primarily of interest on $2.9 million in convertible and other promissory notes we issued during 2014, 2015 and 2016, most of which was converted or redeemed by December 31, 2016.

 

Other Income (Expense), Net.

Other income (expense), net;net, consists primarily of recognized change in value of short-term investments and income (expense) related to the year-over-year fair market value adjustment of our derivative warrant and the net gain or losses on extinguishmentfrom the disposition of convertible and non-convertible, secured and unsecured promissory notes.fixed assets.

 

Income Taxes

 

Deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities, as well as a consideration of net operating loss and credit carry forwards, using enacted tax rates in effect for the period in which the differences are expected to impact taxable income. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company’s effective tax rate has been affected by the full valuation allowance on the Company’s deferred tax assets.

Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits, due to our uncertainty of realizing a benefit from those items. As of December 31, 2016, we hadAt September 30, 2019, the Company has federal net operating loss carryforwards of $34.0 million which begin to expire in 2021 and state net operating loss carryforwards of $27.8approximately $59.4 million which beganand $46.0 million, respectively, not considering any potential Internal Revenue Code of 1986 (“IRC”) Section 382 annual limitation discussed below. The federal loss carryforwards begin to expire in 2016,2023, unless previously utilized.

Approximately $10.5 million of those federal loss carryforwards, however, do not expire due to changes in U.S. tax law under the Tax Cuts and Jobs Act of 2017. Additionally, the utilization of the net operating loss and tax credit carryforwards could be subject to an annual limitation under IRC sections 382 and 383, and similar state tax provisions due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes limit the amount of net operating loss carryforwards and other deferred tax assets that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by IRC Sections 382 and 383. results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percent points over a three-year period. The Company has not conducted an analysis of an ownership change under IRC Section 382. To the extent that a study is completed, and an ownership change is deemed to occur, the Company’s ability to utilize its net operating losses could be limited.


Comparison of the Three and Nine Months Ended September 30, 20172019 and 20162018

 

The following table summarizes our results of operations for the three and nine months ended September 30, 20172019 and 2016:2018:

 

SENESTECH, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except shares and per share data)

(Unaudited)

 For the Three Months For the Nine Months 
 For the Three Months  For the Nine Months  Ended September 30, Ended September 30, 
 Ended September 30,  Ended September 30,  2019 2018 2019 2018 
 2017 2016 2017 2016          
Revenue:                  
License revenue $  $131  $  $261 
Product Sales  17      34    
Total revenue  17   131   34   261 
Cost of goods sold  11      27    
Gross profit  6   131   7   261 
Sales $36  $105  $79  $160 
Cost of sales  25   114   58   153 
Gross profit (loss)  11   (9)  21   7 
                                
Operating expenses:                                
Research and development  721   829   2,517   1,964   432   476   1,359   1,746 
General and administrative  2,235   1,932   7,506   5,259 
Selling, general and administrative  2,173   2,013   5,908   7,506 
Total operating expenses  2,956   2,761   10,023   7,223   2,605   2,489   7,267   9,252 
                                
Net operating loss  (2,950)  (2,630)  (10,016)  (6,962)  (2,594)  (2,498)  (7,246)  (9,245)
                                
Other income (expense):                                
Interest income  9      20      19   1   45   8 
Interest expense  (33)  (6)  (54)  (49)  (10)  (16)  (34)  (60)
Interest expense, related parties     (9)  (1)  (43)
Loss on extinguishment of unsecured promissory note     (59)     (171)
Other income (expense)  37      76   51   -   13   (3)  19 
Total other income (expense)  13   (74)  41   (212)  9   (2)  8   (33)
                                
Net loss  (2,937)  (2,704)  (9,975)  (7,174)
Net loss and comprehensive loss  (2,585)  (2,500)  (7,238)  (9,278)
Deemed dividend-warrant price protection adjustment  -   333   -   333 
Net loss attributable to common shareholders $(2,585) $(2,833) $(7,238) $(9,611)
                                
Series A convertible preferred stock dividends     (30)     (90)
                                
Net loss and comprehensive loss $(2,937) $(2,734) $(9,975) $(7,264)
Weighted average common shares outstanding - basic and fully diluted  27,891,501   20,862,216   25,336,837   18,036,982 
                
Net loss per common share - basic and fully diluted $(0.09) $(0.14) $(0.29) $(0.53)

Three Months Ended September 30, 20172019 compared to Three Months Ended September 30, 2016:2018:

Net Sales

 

Revenue

Revenue was $17,000Net sales were $36,000 for the three months ended September 30, 2017, compared2019 and $105,000 for the same period in 2018. Sales were lower in 2019 due to $131,000 for three months ended September 30, 2016.the transition to the removal of ContraPest’s ‘restricted use only’ status at the state level and our shift to a pull through sales strategy directed at end users. This strategy has shown significant initial promise however, we have experienced an increase in lead-to-conversion time resulting in a longer sales process.

 

The $17,000 revenue recognizedCost of Sales

Cost of sales was $25,000 for the three months ended September 30, 2017 represented sales of our product, ContraPest. The $131,000 of revenue2019, compared to $114,000 for the three months ended September 30, 2016, was earned from research grants2018. Cost of sales were lower in 2019 due to lower sales volume in the third quarter of 2019 and from our former license agreementno scrap expense associated with Neogen, which was terminated in January 2017. We did not recognize any license fees in 2017 under this agreement.manufacturing scale up activities that were experienced during the third quarter of 2018.

 

Cost of Goods SoldGross Profit

 

Cost of goods sold was $11,000Gross profit for the three months ended September 30, 2017,2019 was $11,000 or 30.6% of net sales, compared to $-0-a gross loss of ($9,000) or 8.6% of net sales, for three months ended September 30, 2016.the same period in 2018. The increase in costgross profit was a direct result of goods sold correspondeda decrease in scrap related to the product launch of ContraPest.

scaleup activities.


Research and Development Expenses

 

 Three Months Ended
September 30,
 Increase /  Three Months Ended
September 30,
  Increase  
 2017 2016   (Decrease)  2019  2018  (Decrease) 
 (in thousands)  (in thousands) 
Direct research and development expenses:              
Unallocated expenses:              
Personnel related (including stock-based compensation) $449 $701 $(252)  $206  $274  $(68)
Professional Fees/Consultants 39 10 29 
Facility related 76 51 25 
Facility-related  60   57   3 
Other  157  67  90   166   145   21 
Total research and development expenses $721 $829 $(108)  $432  $476  $(44)

 

Research and development expenses were $721,000$432,000 for the three months ended September 30, 2017,2019, compared to $829,000$476,000 for the same period in 2016.2018. The $108,000$44,000 decrease in research and development expenses was primarily due to a decrease of $252,000$68,000 in personnel-related costs, offset by increasesincluding stock-based compensation expense, due to the classification of certain field support employees to sales and marketing and option grants fully vesting resulting in professional fees/consultant expenseslower expense. With more focus on commercialization of $29,000, facility expenses of $25,000 and other expenses of $90,000. The decrease in personnel-related costs resulted from lowerContraPest, we determined that these certain field support employees previously classified as research and development salariesare now refocused on sales and marketing efforts and thus, reclassified as such.

Facility-related expense increased $3,000 due primarily to facility lease payment escalation.

The increase in other research and development expenses of $219,000 due to reduced headcount and a decrease in stock-based compensation expense of $50,000, offset by higher payroll taxes of $17,000. Professional services and consulting expenses increased $29,000 for the three months ended September 30, 2017, compared to the same period in 2016$21,000 was primarily due to an increase in synthetic triptolide research fees and legal fees. Rent and utilities for the three months ended September 30, 2017 increased $25,000 over the same period in 2016 due primarily to the expansion into the research space at Northern Arizona Center for Entrepreneurship and Technology (“NACET”) facility. Othera reclass of other expenses increased by $90,000 from $67,000 for the three months ended September 30, 2017 as compared to the same period in 2016, primarily due to increased travel expenses of $34,000 related to certain field team support dueemployees to on-site evaluations of potential customerssales and research operations and increased depreciation expense of $70,000 due to fixed asset additions in our research operations offset by lower lab fees of $14,000. As noted last quarter, we have now filed in all 50 states and the District of Columbia and have begun the process of refiling in some states.marketing as described above.

 

We continue to investigate applications of our core technology to other product candidates, which includes laboratory tests and academic collaborations. We also continue to develop our supply chain, particularly identifying and improving our sourcing of triptolide, a key active ingredientingredients for our product candidates.

 

Selling, General and Administrative Expenses

 

GeneralSelling, general and administrative expenses were approximately $2.2 million for the three months ended September 30, 2017,2019, as compared to $1.9approximately $2.0 million for the three months ended September 30, 2016.2018. The increase of $0.3 million$200,000 in selling, general and administrative expenses was primarily due to an increaseincreases in salary and wages expenses associated with the reclassification of $228,000 in personnel related expenses, an increasecertain field support employees from research and development of $89,000 in insurance expenses related to the$100,000 and increased D&O insurance expense as a public company, an increase of $18,000 in non-capitalized furniture and computer equipment and an increase in occupancyprofessional services expenses of $8,000, offset by a $24,000 decrease in professional services fees due primarily to lower audit and accounting fees and a $20,000 reduction in travel and entertainment expenses. The increase in personnel related expenses consisted of an increase of $144,000 in net additional salary costs, an increase in stock based compensation of $61,000, an increase in payroll taxes and processing fees of $35,000 and an increase of $32,000 in recruiting expenses offset by a $44,000 reduction in employee benefits$100,000 due to reduced relocation and benefits costs.increased legal activity in the quarter ending September 30, 2019.

 

Interest Income/Expense, Net

 

We recorded interest income of $9,000, net, for the three months ended September 30, 2019, as compared to interest expense, net of $15,000 for the same period in 2018. The $24,000 increase in interest income, net for the period was a result of decreased interest on capital leases and promissory notes that expired during 2019 and higher interest income as a result of higher average daily cash balances and interest rates year over year.

Other Income (Expense)

We recorded no other income/expense, net, for the three months ended September 30, 2017,2019, compared to $6,000$13,000 of other income for the same period in 2016.2018. The increase in interest expense of $18,000 was the result of increased debt in the form of notes payable and leases on equipment acquisitions during 2017.

Other Income (Expense), Net

We recorded $37,000 of other income, net for the three months ended September 30, 2017, compared to $59,000 of other expense for the same period in 2016. The $96,000$13,000 net decrease in other expenseincome was primarily due to lower expense related to thedecreased, year-over-year fair market value adjustment of our convertible promissory notes and losses on the extinguishment of said promissory notes.derivative warrant.

 


Nine Months Ended September 30, 20172019 compared to Nine Months Ended September 30, 20162018::

Revenue

Net Sales

 

Revenue was $34,000Net sales were $79,000 for the nine months ended September 30, 2017, compared2019 and $160,000 for the same period in 2018. Sales were lower in 2019 due to $261,000 for nine months ended September 30, 2016.the transition to the removal of ContraPest’s ‘restricted use only’ status at the state level and our shift to pull through sales strategy directed at end users. This strategy has shown significant initial promise however, we have experienced an increase in lead to conversion time resulting in a longer sales process. 

 

The $34,000 revenue recognizedCost of Sales

Cost of sales was $58,000 for the nine months ended September 30, 2017 represented sales of our product, ContraPest. The $261,000 of revenue2019, compared to $153,000 for the nine months ended September 30, 2016 was earned from research grants2018. Cost of sales were lower in 2019 primarily due to lower sales volume and from our former license agreementno scrap expense associated with Neogen, which was terminated in January 2017. We did not recognize any license fees in 2017 under this agreement.manufacturing scale up activities that were experienced during 2018.

 

Cost of Goods SoldGross Profit

 

Cost of goods sold was $27,000Gross profit for the nine months ended September 30, 2017,2019 was $21,000 or 26.6% of net sales, compared to $-0-a gross profit of $7,000 or 4.4% of net sales, for nine months ended September 30, 2016.the same period in 2018. The increase in costgross profit was a direct result of goods sold corresponded to the product launch of ContraPest. Cost of goods sold as a percentage of sales for the period was approximately 80%decrease in scrap due to manufacturing inefficiencies surrounding the start-up of the new manufacturing line and the cost of replacement product shippedrelated to replace damaged product.scaleup activities.


Research and Development Expenses

 

 Nine Months Ended
September 30,
 Increase/  Nine Months Ended
September 30,
  Increase 
 2017  2016  (Decrease)  2019  2018  (Decrease) 
 (in thousands)  (in thousands) 
Direct research and development expenses:                   
Unallocated expenses:                        
Personnel related (including stock-based compensation) $1,471  $1,384  $87  $661  $1,124  $(463)
Professional Fees/Consultants  272   142   130 
Facility related  228   157   71 
Facility-related  184   172   12 
Other  546   281   265   514   450   64 
Total research and development expenses $2,517  $1,964  $553  $1,359  $1,746  $(387)

 

Research and development expenses were $2.5$1.4 million for the nine months ended September 30, 2017,2019, compared to $2.0$1.7 million for the same period in 2016.2018. The $500,000 increase$300,000 decrease in research and development expenses was partiallyprimarily due to an increasea decrease of $87,000 in personnel-related costs. This increase$463,000 in personnel-related costs, resulted from increasedincluding stock-based compensation expense, due to the classification of certain field support employees to sales and marketing offset by an increase in depreciation expense of $143,000. With more focus on commercialization of ContraPest, it was determined that these certain field support employees previously classified as research and development salaries of $47,000are now refocused on sales and marketing efforts and thus, reclassified as such.

Facility-related expense increased $12,000 due primarily to headcount additions in 2017 and anfacility lease payment escalation.

The increase in stock-based compensation expenseother research and development expenses of $40,000. Professional services and consulting expenses increased $130,000 for the nine months ended September 30, 2017 compared to the same period in 2016$64,000 was primarily due to an increase in synthetic triptolide research fees and legal fees.

State registration and filing fees increased $27,000 for the nine months ended September 30, 2017 compared to the same period in 2016 due to the increase in state filings and registrations as we have now filed in all 50 states and the Districta reclass of Columbia and have begun the process of refiling in some states. Travelother expenses related to certain field team support increased $97,000 for nine months ended September 30, 2017 over the same period in 2016 dueemployees to on-site evaluations of potential customerssales and research operations. Rent and utilities for the nine months ended September 30, 2017 increased $51,000 over the same period in 2016 due to the expansion into the research space at our NACET facility. Depreciation expense increased $62,000 for the nine months ended September 30, 2017 over the same period in 2016 due to fixed asset additions in our research operations.marketing as described above.

 


We continue to investigate applications of our core technology to other product candidates, which includes laboratory tests and academic collaborations. We also continue to develop our supply chain, particularly identifying and improving our sourcing of triptolide, a key active ingredientingredients for our product candidates.

 

Selling, General and Administrative Expenses

 

GeneralSelling, general and administrative expenses were approximately $5.9 million for the nine months ended September 30, 2019, as compared to approximately $7.5 million for the nine months ended September 30, 2017, compared2018. The decrease of $1.6 million in selling, general and administrative expenses was primarily due to $5.3lower stock compensation expenses of $2.3 million associated with inducement warrants issued in June 2018 and $347,000 due to option grants fully vesting and resulting in lower stock compensation expense, offset by increased salary and wages of $605,000 associated with the reclassification of certain field support employees and an increase of $348,000 in professional services expense. The increase in professional services expenses was primarily due to increased legal and Board of Directors related expenses. 

Interest Income/Expense, Net

We recorded interest income of $11,000, net, for the nine months ended September 30, 2016.2019, as compared to interest expense, net of $52,000 for the same period in 2018. The increase of $2.2 million in general and administrative expenses was due to an increase of $1.5 million in personnel related expenses, an$63,000 increase in travel expensesinterest incomes was a result of $113,000, an increase in insurance expense of $248,000, a $178,000 increase in office suppliesdecreased interest on capital leases and non-capitalized furniturepromissory notes that expired during the nine months ended September 30, 2019, and computer equipment and an increase in marketing, stock service and shareholder relations expenses of $23,000. The increase in personnel related expenses consisted of an increase in stock based compensation of $450,000 and an increase of $1.1 million in net additional salary costs. The increase in insurance was primarily due to increased director and officer insurancehigher interest income as a result of the public becoming a public reporting company in December of 2016. Likewise, marketing, stock servicehigher average daily cash balance and shareholder relations expenses increased due to the Company becoming a commercial, public reporting company in December of 2016.interest rates year over year.

 

Interest ExpenseOther Income (Expense)

 

We recorded $35,000$3,000 of interestother expense, net, for the nine months ended September 30, 2017,2019, compared to $92,000$19,000 of other income for the same period in 2016.2018. The decrease in interest expense of $57,000 was the result of a decrease of $2.9 million in convertible notes that were issued in 2014 and exchanged for Series B convertible preferred stock in December 2016 partially offset by the increase in interest related to increased debt in the form of notes payable and leases on equipment acquisitions during 2017.

Other Income (Expense), Net

We recorded $76,000 of other income, net, for the nine months ended September 30, 2017, compared to $120,000 of other expense for the same period in 2016. The $196,000$22,000 net decrease in other expenseincome was primarily due to the expense related to thedecreased, year-over-year fair market value adjustment of our convertible promissory notes and losses on the extinguishmentderivative warrant as well as recognition of said promissory notes.$3,000 of loss due to disposal of certain fixed asset during 2019.

 


Liquidity and Capital Resources

  

Since our inception, we have sustained significant operating losses in the course of our research and development activities we have sustained significant operating losses and expectscommercialization efforts and expect such losses to continue for the near future. We have generated limited revenue to date from product sales, research grants and licensing fees received under our former license agreement with Neogen. During the first nine months ofIn 2017, we began full scale marketing of our first product, ContraPest and we continue to develop other product candidates, which are in various phases of development.ContraPest. We have funded our operations to date primarily with proceeds fromthrough the sale of equity securities, including convertible preferred stock, common stock and preferred stock, the issuancewarrants to purchase common stock; debt financing, consisting primarily of convertible and other promissory notesnotes; and, to a lesser extent, payments received underin connection with product sales, research grants and pursuant to our former license agreement with Neogen.licensing fees. Through September 30, 2017,2019, we had received net proceeds of $49.2$67.2 million from our sales of common stock, and preferred stock and warrant exercises and issuance of convertible and other promissory notes, an aggregate of $1.7 million from licensing fees and an aggregate of $1.6$0.5 million from licensing fees. in net product sales. At September 30, 2019, we had an accumulated deficit of $93.1 million and cash and cash equivalents of $3.9 million.

 

The Company’sOur ultimate success depends upon the outcome of a combination of factors, including: (i) the success of its research and development; (ii) ongoing regulatory approval andsuccessful commercialization of ContraPest and its othermaintaining and obtaining regulatory approval of our products and product candidates; (iii)(ii) market acceptance, and commercial viability and profitability of ContraPest and other products if the Company obtains the necessary regulatory approvals; (iv)products; (iii) the ability to market itsour products and establish an effective sales force and marketing infrastructure to generate significant revenue; (iv) the success of our research and development; (v) the ability to retain and attract key personnel to develop, operate and grow itsour business; and (vi) the timely and successful completion of additional financing as needed. The Company has funded its operationsour ability to date through the sale of convertible preferred stock and common stock, including an initial public offering of 1,875,000 shares of its common stock on December 8, 2016, debt financing, consisting primarily of convertible notes and, to a lesser extent, payments received in connection with research grants and licensing fees. As of September 30, 2017, we had an accumulated deficit of $71.3 million and cash and cash equivalents and highly liquid investments of $3,648.meet our working capital needs.

Based upon itsour current operating plan, the Company expectswe expect that cash and cash equivalents and highly liquid, short term investments at September 30, 2017,2019, in combination with anticipated revenue and any additional sales of our equity securities, will be sufficient to fund itsour current operations for at least the near future. However,next six months. We have taken and will continue to take actions to reduce our operating expenses and to concentrate our resources toward the Company issuccessful commercialization of ContraPest in the U. S. however, if anticipated revenue targets and margin targets are not achieved and we are unable to raise necessary capital through the sale of our securities, we may be required to take other measures that could impair our ability to be successful and operate as a going concern. In any event, we are likely to require additional capital in order to fund itsour operating losses and research and development activities by issuing additionaluntil we become profitable. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to need to raise capital through equity or debt and equity instruments, until such time as the Company is profitable.financing. If such equity or debt financing is not available at adequate levels the Company willor on acceptable terms, we may need to reevaluate its plans.delay, limit or terminate commercialization and development efforts.

Off-Balance Sheet Arrangements

As of September 30, 2017, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of SEC Regulation S-K.


 

Additional Funding Requirements

We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we market and focus on sales of ContraPest, and as we advance field studies of our product candidates in development. In addition, we will continue to incur additional costs associated with operating as a public company.

 

In particular, we expect to incur substantial and increased expenses as we:

 

Continue the researchWork to maximize market acceptance for, and developmentgenerate sales of, ContraPest and our other product candidates, including engaging in any necessary field studies;products;

 

Seek ongoing regulatory approvals for ContraPest and our other product candidates;

Scale up manufacturing processes and quantities to prepare forManage the commercialization of ContraPest and any other product candidates for which we receive regulatory approval;

Establish an infrastructure for the sales, marketing and distribution of ContraPest and any other product candidates for which we may receive regulatory approval;

 

Attempt to achieve market acceptance forContinue the development of ContraPest and our products;other product candidates, including engaging in any necessary field studies;

 

ExpandSeek additional regulatory approvals for ContraPest and our other product candidates;

Scale up manufacturing processes and quantities to meet future demand of ContraPest and any other product candidates for which we receive regulatory approval;

Continue product development of ContraPest and advance our research and development activities and advance the discoveryresearch and development programs for other product candidates;

 

Maintain, expand and protect our intellectual property portfolio; and

 

Add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts and operations as a public company.


Cash Flows

 

The following table summarizes our sources and uses of cash for each of the periods presented:

 

 Nine Months Ended
September 30,
 
 Nine Months Ended
September 30,
  2019  2018 
 2017  2016    
Cash used in operating activities $(7,596) $(4,240) $(6,092) $(6,916)
Cash used in investing activities  (3,825)  (54)
Cash (used in) provided by investing activities  (64)  2,592 
Cash provided by financing activities  294   5,498   5,181   7,014 
Net increase (decrease) in cash and cash equivalents $(11,127) $1,204 
Net (decrease) increase in cash and cash equivalents $(975) $2,690 

 

Operating Activities.

 

During the nine months ended September 30, 2017,2019, operating activities used $7.6$6.1 million of cash, primarily resulting from our net loss of $10.0$7.2 million offset by changes in our operating assets and liabilities of $154,000 and by non-cash charges of $992,000, consisting primarily of stock-based compensation, depreciation and amortization. Our net loss was primarily attributable to research and development activities and our selling, general and administrative expenses, as we generated limited product revenue during the period. Net cash provided by changes in our operating assets and liabilities for the nine months ended September 30, 2019, consisted primarily of a net increase in accrued expenses and accounts payable of $164,000, a decrease in prepaid expenses of $38,000 and a decrease in deposits of $3,000 offset by an increase in inventory of $24,000, an increase in receivables of $16,000 and a decrease in deferred rent of $11,000.


During the nine months ended September 30, 2018, operating activities used $6.9 million of cash, primarily resulting from our net loss of $9.3 million and by changes in our operating assets and liabilities of $0.6$1.1 million, partially offset by non-cash charges of $3.0 million.$3.4 million, consisting primarily of stock-based compensation, depreciation and amortization. Our net loss was primarily attributedattributable to research and development activities and our selling, general and administrative expenses, as we generated limited product revenue during the period. Net cash used by changes in our operating assets and liabilities for the nine months ended September 30, 20172018 consisted primarily of an increase in inventory of $578,000, prepaid expenses of $166,000, a decrease in prepaidaccounts payable/accrued expenses of $165,000$251,000, an increase in receivables of $36,000 and a decrease in receivables of $3,000 and an increase in deferred rent of $12,000,$18,000, offset by a net decrease in accrued expenses and accounts payable of $473,000, a net increase in inventories of $337,000 and an increase in deposits of $8,000. The net decrease in accrued expenses and accounts payable was primarily due to timing of expense occurrence and payables management, offset by our payment of the $1.0 million contract cancellation settlement accrual in January. 


During the nine months ended September 30, 2016, operating activities used $4.2 million of cash, primarily resulting from our net loss of $7.2 million, partially offset by non-cash charges of $3.0 million and by cash provided by changes in our operating assets and liabilities of $62,000. Our net loss was primarily attributed to research and development activities and our general and administrative expenses, as we generated limited research grant and licensing revenue during the period. Net cash provided by changes in our operating assets and liabilities for the nine months ended September 30, 2016 consisted primarily of a $175,000 decrease in deferred revenue related to our license agreement with Neogen and a $202,000 decrease in accrued expenses and accounts payable. The decrease in accrued expenses and accounts payable was due to increased payments as a result of the receipt of cash raised in financing activities.$7,000.

 

Investing ActivitiesActivities.

 

For the nine months ended September 30, 2017,2019, we used $3.8 million$64,000 in net cash related to investing activities consisting of $2.9 million of purchases in securitiesdue to be held to maturity and $885,000 in purchases of property and equipment.

 

For the nine months ended September 30, 2016, we used $54,0002018, net cash of cash in$2.6 million was provided by investing activities consisting of $2.6 million of proceeds received from the sale of securities and $185,000 of proceeds from the sale of equipment offset by $212,000 in purchases of property and equipment.

 

Financing ActivitiesActivities.

 

During the nine months ended September 30, 2017,2019, net cash generated fromprovided by financing activities was $294,000$5.2 million as a result of $437,000 of$3.6 million in net proceeds from the issuance notes payableof common stock and net proceeds of $1.8 million from the exercise of warrants offset by payments of $66,000$184,000 related to notes payable and $55,000 of payments for employee withholding taxes related to share-based awards.

During the nine months ended September 30, 2018, net cash provided by financing activities was $7.0 million as a result of $5.1 million in proceeds from the issuance of common stock, net, $2.2 million in proceeds from warrant exercises and $9,000 in proceeds from issuances of notes, offset by $248,000 of repayments of related to notes payable and notes payable, related party, and $77,000$50,000 in paymentsrepayments of capital lease obligations.obligations and $42,000 of payments for employee withholding taxes related to share-based awards.

  

During the nine months ended September 30, 2016, net cash provided by financing activities was $5.5 million as a result of $6.2 million of proceeds from the issuance of shares of common stock in our rights offering discussed elsewhere in this prospectus, $326,000 of proceeds received from our issuance of notes payable, $896,000 of proceeds received from the issuance of Series B convertible preferred stock, and $449,000 of proceeds received from the exercise of stock options, all of which were partially offset by payments of $1.6 related to the notes, payable, notes payable related party and convertible notes payable, $16,000 of capital lease repayments and $801,000 of deferred offering cost payments.Off-Balance Sheet Arrangements

 

Recent Developments

NoneNone.

 

Critical Accounting Policies and Significant Judgments and Estimates

 

Our financial statements are prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

 


While our significant accounting policies are described in more detail in Note 2 to our financial statements included elsewhere in this Quarterly Report on Form 10-Q, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.


Revenue Recognition

 

We recognize revenue in accordanceEffective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”), Topic 605, Revenue Recognition. Accordingly, we recognizeCompany recognizes revenue from the commercial salesales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured.

 

We have generated revenue fromThere was no impact on the Company’s financial statements as a license agreement with a strategic partner pursuant to which we had granted to such partner the exclusive license in North America to manufacture, distribute and sell commercial control products based on our intellectual property, which includes ContraPest,result of adopting ASC 606 for the later of 10 years or the expiration of the patent for ContraPest (if issued).

The license agreement was subsequently terminated on January 23, 2017.

When we receive non-refundable, upfront license fee payments for the exclusive rights to licensing our intellectual property, management determines if such license has stand-alone value. Since management determined that the license to our intellectual property did not have stand-alone value, we recognized revenue attributable to that license on a straight-line basis over the estimated related performance period. Any changes in the estimated period of performance will be accounted for prospectively as a change in estimate.

Our licensing agreement also provided for a future fixed amount of contingent milestone paymentsthree months and contingent sales-based royalties to be received upon the achievement of milestone events. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achievednine months ended September 30, 2019 and the milestone payments are due and collectible. A milestone is considered substantive when the consideration payable to us for such milestone has all of the following characteristics: (1) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved; (2) the event can only be achieved based in whole or part on either our performance or a specific outcome resulting from our performance; and (3) if achieved, the event would result in additional payments being due to us. In making this assessment in the future, we will consider all facts and circumstances relevant to the arrangement, including whether any portion of the milestone consideration is related to future performance or deliverables. In addition, we will account for sales-based royalties as revenue upon achievement of certain sales milestones. 2018, respectively.

 

Stock-Based Compensation

 

We recognize compensation costs related to stock options granted to employees based on the estimated fair value of the awards on the date of grant, net of estimated forfeitures, in accordance with ASC Topic 718 —  Stock Compensation (“ASC 718”). We estimate the grant date fair value of the awards, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The grant date fair value of stock-based awards is expensed on a straight-line basis over the vesting period of the respective award. We account for stock-based compensation arrangements with non-employees using a fair value approach. The fair value of these stock options is measured using the Black-Scholes option-pricing model reflecting the same assumptions as applied to employee options in each of the reported periods, other than the expected life, which is assumed to be the remaining contractual life of the option. The fair value of the stock options granted to non-employees is re-measured as the stock options vest and is recognized in the statements of operations and comprehensive loss during the period the related services are rendered.

 

We recorded stock-based compensation expense of approximately $2.8 million$204,000 and $2.4 million$675,000 for the three and nine months ended September 30, 20172019, respectively and 2016,$355,000 and $3.1 million for the three and nine months ended September 30, 2018, respectively. We expect to continue to grant stock options and other equity-based awards in the future, and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase.

 

The Black-Scholes option-pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards. If we had made different assumptions, our stock-based compensation expense, net loss and loss per share of common stock could have been significantly different. Our assumptions are as follows:

 

Expected term.  The expected term represents the period that the stock-based awards are expected to be outstanding. Our historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of a lack of sufficient data. Therefore, we estimate the expected term by using the simplified method, which calculates the expected term as the average of the time-to-vesting and the contractual life of the options.

 


Expected volatility.   Expected volatility is derived from the average historical volatilities of publicly traded companies within our industry that we consider to be comparable to our business over a period approximately equal to the expected term. We intend to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information regarding the volatility of our own common stock price becomes available, or unless circumstances change such that the identified companies are no longer similar to us, in which case, more suitable companies whose share prices are publicly available would be utilized in the calculation.

 

Risk-free interest rate.  The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.

 

Expected dividend.  The expected dividend is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock.

 

Expected forfeitures.  We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.


Significant Factors, Assumptions and Methodologies Used in Determining Fair Value of Our Common Stock

 

As noted above, we are required to estimate the fair value of the common stock underlying our stock-based awards when performing the fair value calculations using the Black-Scholes option-pricing model. Prior to our initial public offering in December 2016, inIn the absence of an active market for our common stock, we previously utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid,Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of our common stock. In addition, we have conducted periodic assessments of the valuation of our common stock.

 

The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. If we had made different assumptions than those used, the amount of our stock-based compensation expense, net income and net income per share amounts could have been significantly different. The fair value per share of our common stock for purposes of determining stock-based compensation expense is the closing price of our common stock as reported on the applicable grant date. The compensation cost that has been included in the statements of operations and comprehensive loss for all stock-based compensation arrangements is as follows:

 

 Three Months Ended September 30,  Nine Months Ended      September 30, 
 Three Months Ended
September 30
 Nine Months Ended
September 30,
  2019  2018  2019  2018 
 2017  2016  2017  2016          
Research and development $85  $135  $269  $309  $1  $29  $11  $87 
General and administrative  861   798   2,549   2,097   203   326   664   3,003 
Total stock-based compensation expense $946  $933  $2,818  $2,406  $204  $355  $675  $3,090 

 

The intrinsic value of stock options outstanding as of September 30, 2017 is $183,000, of which $968,000 and $(785,000) would have been related to stock options that were vested and unvested, respectively, at that date.2019 was $0.

 

Emerging Growth Company Status

 

The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to “opt out” of this provision and, as a result, we intend to comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies.

 


Item 3.Quantitative and Qualitative Disclosures about Market Risk

 

Not applicable.

 

Item4.Item 4.Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintainconducted an evaluation (pursuant to Rule 13a-15(b) of the Exchange Act), under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures that(as defined in Rule 13a-15(e)) as of the end of the period covered by this report.

These disclosure controls and procedures are designed to ensure that the information required to be disclosed in theour reports that we fileare filed or submitsubmitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that this information is accumulated and communicated to our management, including our Chief Executive Officerthe principal executive and Chief Financial Officer (or Acting Principal Financial Officer, as the case may be),principal financial officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Our management conducted an evaluation (pursuant to Rule 13a-15(b)) of

Based on the Exchange Act, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e)) as of the end of the period covered by this report. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that ourthese disclosure controls and procedures were effective as of the end of the period covered by this report.

 

Changes in Internal Control over Financial Reporting

There werewas no changeschange in our internal control over financial reporting that occurred during the three-month periodquarter ended

September 30, 20172019, that havehas materially affected, or areis reasonably likely to materially affect, our internal control over financial reporting.


PART II. OTHER INFORMATION

 

Item 1.Legal Proceedings

 

The Company may be subject toFor information regarding legal proceedings in which we are involved, see Note 12 -- Commitments and claims arising from contracts or other matters from timeContingencies under the subsection titled “Legal Proceedings” in our Notes to timeCondensed Financial Statements in the ordinary coursePart I, Item 1 of business. Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effectthis Quarterly Report on its financial position, results of operations or liquidity.Form 10-Q.

 

Item 1A.Risk Factors

 

Except as detailed below and disclosed in subsequently filed Quarterly Reports on Form 10-Q, thereThere have been no material changes in the risk factors set forth in Part I, Item 1A, “Risk Factors” in our 2018 Annual Report on Form 10-K/A for the year ended December 31, 2016.

Depending on the commercial success of ContraPest, we may require additional capital to fund our operations. Failure to obtain this necessary capital if needed may force us to delay, limit, or terminate our product development efforts or other operations.

Developing product candidates, including conducting experiments and field studies, obtaining and maintaining regulatory approval and commercializing any products later approved for sale, is a time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we advance our commercialization activities. We plan to substantially expand our operations, and as a result of many factors, some of which may be currently unknown to us, our expenses may be higher than expected. Securing additional financing may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates, including ContraPest. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to:Report.

 

Significantly delay, scale back or discontinue the development or commercialization of our product candidates, including ContraPest;

Seek strategic partners for the manufacturing, sales and distribution of ContraPest or any of our other product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; and
Relinquish, or license on unfavorable terms, our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves.

The occurrence of any of the events described above would have a material adverse effect on our business, operating results and prospects and on our ability to develop our product candidates.


If securities or industry analysts, or other sources of information, do not publish research, or publish inaccurate or unfavorable research or other information about our business, our stock price and trading volume could decline.

The trading market for our common stock may depend on the research, reports and other information that securities or industry analysts, or other, third party sources of information, publish about us or our business. We do not have any control over these analysts or other, third party sources of information, and from time to time inaccurate or unfavorable research or other information about our business, financial condition, results of operations and stock ownership may be published. We cannot assure that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our stock price or trading volume to decline. If incorrect or misleading information is disseminated publicly by third parties about us, our stock price could decline.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3.Defaults Upon Senior Securities

Use of Proceeds from Public Offering of Common Stock

None.

 

Item 4.Mine Safety Disclosures

In December 2016, we closed our initial public offering (“IPO”), in which we sold 1,875,000 shares of common stock at a price to the public of $8.00 per share. No shares were sold in connection with the underwriters’ option to purchase additional shares. The offer and sale of all of the shares in the IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-213736), which was declared effective by the SEC on December 7, 2016. We raised approximately $12.6 million in net proceeds after deducting underwriting discounts and commissions of approximately $1.1 million and offering expenses of approximately $1.3 million. Using the proceeds from the IPO, on December 13, 2016, we paid $175,890 to the holder of all of our shares of Series A convertible preferred stock for its agreement to waive all accrued dividends on the Series A convertible preferred stock and convert all of its shares of Series A convertible preferred stock into common stock immediately prior to the consummation of the IPO. No payments were made by us to directors, officers or persons owning 10% or more of our capital stock or to their associates, or to our affiliates, other than payments in the ordinary course of business to officers for salaries. There has been no material change in the planned use of proceeds from our IPO as described in the final prospectus issued in connection with the IPO.  We have invested the remaining proceeds in accordance with our board approved investment policy, which provides for investments in obligations of the U.S. government, money market instruments, registered money market funds and corporate bonds. The managing underwriter of our IPO was Roth Capital Partners, LLC and co-managing underwriters were Craig-Hallum Capital Group LLC and Aegis Capital Corp. 

Not applicable.

 

Item 5.

Other Information

 None.

Effective November 10, 2019, Drs. Loretta Mayer and Cheryl Dyer discontinued their service as Chief Science Officer and Chief Research Officer, respectively, and employment with the company. While the terms of their departures are currently being finalized, under the terms of their current employment agreements, Drs. Loretta Mayer’s and Cheryl Dyer would receive their current salary and paid health insurance for a period of 12 months from the date of employment termination. The Company estimates the liability for this salary and insurance continuation to be $750.

 

In addition, Dr. Jamie Bechtel, currently lead independent director of the Company, succeeds Dr. Mayer as Chairman of the Board. Dr. Mayer remains a Director of the Company.


Item 6.Exhibits

 

The exhibits listed in the Index to Exhibits are filed or incorporated by reference as part of this Quarterly Report on Form 10-Q.

INDEX TO EXHIBITS

 

Exhibit
Number
 Filed or
Furnished Herewith

Incorporated by Reference

DescriptionForm Filing
Date
Exhibit File No.
3.1 Amended and Restated Certificate of Incorporation S-1/A 10/20/20163.3 333-213736
         
3.2Amended and Restated Bylaws S-1 9/21/20163.5 333-213736
         
31.1Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934X      
         
31.2Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934X      
         
32.1Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X      
         
32.2Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X      
         
101.INSXBRL Instance DocumentX      
         
101.SCHXBRL Taxonomy Extension SchemaX      
         
101.CALXBRL Taxonomy Extension Calculation LinkbaseX      
         
101.DEFXBRL Taxonomy Extension Definition LinkbaseX      
         
101.LABXBRL Taxonomy Extension Label LinkbaseX      
         
101.PREXBRL Taxonomy Extension Presentation LinkbaseX      

ExhibitFiled or
Furnished
Incorporated by Reference
NumberDescriptionHerewithFormFiling DateExhibitFile No.
31.1Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934X
31.2Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934X
32.1Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
32.2Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
101.INSXBRL Instance DocumentX
101.SCHXBRL Taxonomy Extension SchemaX
101.CALXBRL Taxonomy Extension Calculation LinkbaseX
101.DEFXBRL Taxonomy Extension Definition LinkbaseX
101.LABXBRL Taxonomy Extension Label LinkbaseX
101.PREXBRL Taxonomy Extension Presentation LinkbaseX
104[Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)][If tagging]

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 SENESTECH, INC.

(Registrant)
   
Dated: November 8, 201714, 2019By:/s/ Loretta P. Mayer, Ph.D.Kenneth Siegel
  Loretta P. Mayer, Ph.D.Kenneth Siegel
  Chair of the Board, Chief Executive Officer and
Chief Scientific Officer
   
Dated: November 8, 201714, 2019By:/s/ Thomas C. Chesterman
  Thomas C. Chesterman
  Chief Financial Officer and Treasurer

 

33